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HEALTH STATUS MEASUREMENT IN SURGICAL PRACTICE
The Doctor next morning was rubbing his hands,
And saying, "There's nobody quite understands
These cases as I do! The cure has begun!
How fresh the chrysanthemums look in the sun!"
The Dormouse lay happy, his eyes were so tight
He could see no chrysanthemums, yellow or white.
And all that he felt at the back of his head
Were Delphiniums (blue) and geraniums (red).
A. A. Milne
from "The Dormouse and the Doctor"
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All of the work described in the following thesis has been performed exclusively
by myself, except for the following:
The advanced breast cancer study at Guy's Hospital was conducted by Dr
Amanda Ramirez, who collected the Qualitator data.
In the abdominal pain study at the William Harvey Hospital, Dr Kevin
Smith initiated the study and, with Dr Meena Agarawal, helped to collect the
data on admission of the patients. Mrs Margaret Harrison amassed the returned
postal questionnaires.
For the minor surgery study in King's College Hospital, Mr Hamid
Khawaja and Mr Nigel Heaton collected the preoperative data.
Simon C A Fraser
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HEALTH STATUS MEASUREMENT IN SURGICAL PRACTICE
Abstract
In the last hundred years, improved social conditions and advances in
medical science have rendered previously fatal conditions curable. Modern
surgical practice is now too complex to be measured by mortality and morbidity
alone. Subjective, patient derived outcome measures are slowly gaining
influence in other fields. Health status, or Quality of Life (QoL), measurement
has not been widely adopted in surgical practice. To test the hypothesis that
Health status measures, scientifically applied, provide important additional
information to the surgeon, the techniques were applied to three diverse areas
of surgical practice as models for broader application.
Chemotherapy for advanced breast cancer patients
Chemotherapy has little effect on survival in patients with advanced
breast cancer. UICC response and toxicity criteria are used to measure
outcome and QoL measurement is a rarity. Using a diary developed to make
QoL measurement simpler, a randomised trial was mounted to compare QoL
scores in patients receiving two regimens of differing toxicity. Forty patients
received CMF or Epirubicin and were evaluated according to UICC criteria, the
Nottingham Health Profile (NHP), Linear Analogue Self-Assessment (LASA) and
King's diary. Response rates were better and toxicity worse for patients
receiving CMF, but survival was the same for both regimens. Survival and QoL
were better for responders than for non-responders, irrespective of therapy.
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Good initial QoL scores predicted a response, and longer survival and these
findings were repeated in a separate study at Guy's Hospital.
Psychological screening for Non Specific Abdominal Pain
Patients with Non Specific Abdominal Pain (NSAP) are significant
consumers of surgical resources but a psychological contributor is often
suspected. To determine whether NSAP has a detectable psychological
contributor which could be used to predict outcome, 131 patients aged 14-40
admitted with acute abdominal pain were assessed using the General Health
Questionnaire and Hospital Anxiety and Depression questionnaires, and a
structured interview. In 61 patients with NSAP, more had a psychosocial
problem identified by the admitting registrar (x =7.28,ldf,p<0.01) and marginally
more had high questionnaire scores. The risk of having NSAP was high if an
abnormality on interview accompanied high questionnaire scores (Relative Risk
1.93, 95%c.i. 1.35-2.77) or if prodromal pain had lasted more than 7 days
(relative Risk 2.13: 1.55-2.92). After 2 years, patients with continuing pain had
higher HAD (x^=6.57, ldf,p<0.02) and Spielberger anxiety trait
(x =6.50,ldf,p<0.02) scores; NSAP was associated with persisting pain (Relative
Risk 2.22, 1.10-4.48). Psychosocial factors are implicated in NSAP and in
chronic pain, but the sensitivity and specificity of questionnaire assessment are
too low to be useful in diagnosing NSAP. What promotes NSAP still remains
largely unknown, but the referral process may be the next direction for
productive study.
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Health status after minor surgery
To establish whether minor operations cause a perceived and measurable
improvement in health and QoL, 57 patients having day-surgery on a Waiting
List Initiative were studied prospectively. The NHP, HAD and GHQ were
completed before surgery and after 6 months by 81% patients, when an ad-hoc
questionnaire dwelling on perceived outcome of surgery was also completed. An
operative success was reported by 78%, improved health by 64%, improved QoL
by 69% and improved work efficiency by 54%. Improvements in HAD anxiety
(p=0.023), depression (p=0.035), NHP pain (p=0.001) and global NHP (p=0.034)
were recorded. In the perceived outcome questionnaire, patients reporting a
successful operation had had better preoperative GHQ (p=0.029) and HAD
depression (p=0.031) scores than those whose operation was not a success. Those
reporting an improvement in health postoperatively had worse preoperative NHP
scores to start with (p=0.027) than those who had no improvement. Minor
surgery results in improvements in both perceived and in objectively measured
health and QoL. Both are valid outcome measures for minor surgery.
Preoperative scores may be related to subsequent perception of outcome.
Health status measurement using validated measures and specially
developed measures can yield valuable and unexpected prognostic, prospective
and retrospective information on the process and outcome of treatment, on
individuals and populations. There are important logistic problems in the
gathering of accurate QoL data but the techniques potentially have an important





The teachings of Hippocrates provided the basis on which medicine was
taught from the third century before Christ onward. His ethical ideal forms the
foundation of medical practice today. He realised the importance of
documenting all possible variations in each individual patient and then deducing
their relevance to the disease condition:
"We must consider the patient, what food is given to him and who gives it..., the
conditions of climate and locality both in general and in particular, the patient's
customs, mode of life, pursuits and age. Then we must consider his speech, his
mannerisms, his silences, his thoughts, his habits of sleep or wakefulness and his
dreams, their nature and time."
He recognised that the outcome of medical treatment was not necessarily
beneficial: "Practise two things in your dealings with disease: either help or do
not harm the patient".
And even at this early stage in the evolution of professionalised medicine, he
warned of the dangers of the quacks:
"If their patient be cured, their reputation for cleverness is enhanced, while, if
he dies, they can excuse themselves by explaining that the gods are to blame
while they themselves did nothing wrong." (Lloyd, 1978)
In the intervening two millennia, the documentation and categorisation
of disease has reached great sophistication. The teaching of physic was
conducted at the highest academic level in the great teaching centres of the
classical world. Surgical treatments were described for many conditions
including bowel obstruction and breast cancer. During the Renaissance, a new
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era dawned. One of the most prominent surgeons in France, Ambrose Pare
(1510-90), echoing Hippocrates, entreated the physician, "First do no harm" (De
Moulin, 1989). His teachings on surgical technique reached a wide readership.
In England and in Scotland, however, the barber surgeon was reviled by the
learned physicians, as he was not classically or medically educated. The craft
guild of Barber Surgeons of Edinburgh was incorporated by the Town Council in
1505, but surgery did not form a part of university medical education until the
18th century, during the "age of enlightenment". The golden era of hypothetico-
inductive reasoning produced advances in understanding and in technique in all
branches of medicine, and the art and the science of medicine became
inextricable (Baum, 1989a).
The advances which have taken place up until the present day have
embodied the early entreaties of Hippocrates. Until relatively recently, the
results of treatment could be measured best in terms of death, disability or cure
but more usually, simply the former or the latter. Despite the increasing
sophistication of new medical and surgical treatments during the latter half of
the 20th century, there are now many remedies available to the physician and
surgeon which are not measurable in terms of survival. Remarkably little
attention has been given to establishing means of measuring the effect of
treatment- other than in terms of survival. Baum pointed out the pitfalls in
relying upon surrogate outcome measures:
"...Improvements in biochemichal parameters or radiological signs, which may
be used because they are quicker or easier to achieve and encourage us to lose
sight of the simple issues of length and quality of survival." (Baum, 1989b).
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A recurring worry to the profession is that there seems to be increasing
dissatisfaction amongst the patient population with conventional medicine, as
witnessed by the increasing demand for "alternative" remedies (Baum, 1989a).
The old worry, of how to allocate priority in a medical system with finite
resources, is becoming ever more pressing. So how are we to judge which
treatments are the best to be offered, when, to whom and by whom?
1.2 What is to be measured?
The Scottish physicist Lord Kelvin (1824-1907) stated:
"When you can measure what you are speaking of and express it in terms of
numbers you know something about it: when you cannot express it in terms of
numbers your knowledge is of a meagre kind" (Duncan, 1985).
The simplest definition of life divides it into two dimensions- quantity and
quality (Ware, 1987). Quantity is easy to define and measure. Regarding quality
however, the definition alone is a matter worthy of much philosophical discourse
(Pirsig, 1974) and defining quality in health care is, similarly, a taxing exercise
(Donabedian, 1980a). Measurement cannot therefore be straightforward.
Elkington referred to the concept of "Quality of Life" in 1966, as a goal aimed
for by every physician for his patient (Elkington, 1966) but it was not until the
mid-seventies that the term was to become widespread. The term was first
coined by John F Kennedy's presidential commission which set goals for the USA
for the year 2000 (Williams, 1991). Until 1966, the term was used with
reference to post-war consumer activity (Alexander and Willems, 1981) although
the ethos was clearly embodied in the definition of health included in the
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constitution of the World Health Organisation in 1947:
"Health is not only the absence of infirmity, but also a state of physical, social
and mental wellbeing" (WHO, 1947).
1.3 Quality of Life measurement
In the realms of chronic or incurable disease, it has long been recognised
that more subtle factors than simply survival must be taken into account in
assessing treatment. It was an oncologist, David Karnofsky, who developed the
first measure of "performance" (Karnofsky and Burchanal, 1949). This is a 10-
point scale which spans the extremes of physical dependency, as related to
nursing burden, and measured by an observer. For many years this scale was
used extensively, but not always appropriately, to justify or condemn treatments
and not until some 20 years later was it improved upon, with the Activities of
Daily Living scale (Katz et al., 1970). In the two decades which have followed,
a profusion of scales and questionnaires (called "instruments") have been
developed, primarily to measure health status in patients with cancer or chronic
disease, and primarily to compare treatments in the context of trials. They
have in common the goal of measurement. However, the construct being
measured differs depending upon the instrument. The terminology which has
evolved to describe these is sometimes confusing. The terms "health status" and
"quality of life" tend to be used interchangeably. However, Spitzer advises that
the former term should be used to describe instruments which are applied
primarily to healthy people, whereas the latter should be used for instruments
which apply to the sick (Spitzer, 1987). Spitzer goes on to describe a third
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category of QoL measures, those designed to test a specific hypothesis. Into
these three broad categories, then, fall all known QoL instruments, now in
excess of 50.
1.4 Quality of life instruments
Many instruments now exist, to measure QoL in general terms, or health
status in specific illnesses. There are certain features common to all. Almost
all are now self-assessment instruments, designed to remove the potential for
observer bias. Poor observer-respondent correlation in health status and QoL
measurement is a well documented phenomenon (Slevin et al., 1988; Brewster
and Newman, 1991). Epstein et al. found poor correlation between the scores
of proxies and subjects compared during structured interviews incorporating
various QoL instruments (Epstein et al., 1989). Only a compelling reason such
as extreme youth should allow a proxy or observer's QoL assessment to have
precedence over that of the subject. All instruments consist of a variable
number of domains, usually 1-6, which contain or gather information focused on
a particular aspect of health and QoL. Ware defined five generic health
concepts, or dimensions: physical health, mental health, social functioning, role
functioning and general health perceptions (Ware, 1987). The Nottingham
Health Profile, perhaps the best known QoL questionnaire, includes six domains:
emotional reactions, energy, pain, physical mobility, sleep, and social isolation
(Hunt et al., 1985). Each domain contains items- which can be complete
questions requiring a yes/no answer (dichotomous) or symptoms inviting the
20
selection of a gradated response on a scale. A scale can be categorical (eg.
very much, somewhat, a little, not at all), or in the form of a visual analogue
scale (VAS), in which a mark is put upon a straight line which spans the
extremities of a particular symptom (Bond and Lader, 1974). There is no
evidence that a VAS is superior or inferior to a categorical scale, nor evidence
that an odd or even number of categories is preferable (Remington et al., 1979),
although McQuay favours a categorical scale where simplicity is paramount
(McQuay, 1990). More than five points are superfluous on a categorical scale
(Lissitz and Green, 1975). The arrival at a final score depends upon the format
chosen. A categorical scale is usually given an ascending integer score
corresponding to the severity with which the symptom or item is perceived (eg
0-4). Each item of a VAS is usually scored on a 10cm line, divided into 10
portions: the mark on the line is given a score 0-9 (or 1-10) depending again
upon severity. Scores for individual items are usually aggregated to produce a
simple score for that domain, but in some measures, eg. the Nottingham Health
Profile, a weighting system is used, so that a positive response for each
(dichotomous) item is multiplied by a factor before aggregation into a score for
that domain (Hunt et al., 1985). Aggregation of the scores from separate
domains into a global QoL score is a prevalent practice, but in certain
circumstances may detract from rather than add to the precision of the data.
The timeframe of a QoL instrument is the period which the respondent
is being asked to consider in formulating a response. Many QoL measures leave
the timeframe undefined. Alternatively, patients may be asked to consider the
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previous day, week, or month before formulating a response (Aaronson, 1988).
The periodicity or variability of the condition will dictate the choice of
timeframe and for certain instruments, the timeframe is built into the
instrument design, for instance a diary card.
1.5 Validity of quality of life instruments
QoL instruments in common usage have all been through a process of
development. Briefly, the process involves selection of items, their reduction
in number, design of format, pretesting, reliability testing (for repeatability),
responsiveness (comparison with the change in other parameters, eg. objective
toxicity) and validity. Validation takes the longest time in instrument
development and needs time, and patient numbers. Face validity includes the
clarity, user-friendliness and how comprehensively the subject is covered;
criterion validity uses measurement against an empirical measure (eg a dyspnoea
question measured against a treadmill)(Aaronson, 1988); construct validity is the
predictability with which items and domains relating to eachother (Guyatt et al.,
1986).
As examples of instruments and their developmental processes, some
attention will be given to instruments which appear later on in this thesis. The
aforementioned Nottingham Health Profile was developed in the latter half of
the 1970s and completed in 1981, as a "self-administered questionnaire designed
to measure perceived health problems and the extent to which such problems
affect normal activities" (Hunt et al., 1981). In the initial stages, 2200
22
statements relating to ill health were compiled by researchers, eg. "I find it
hard to walk upstairs". These were distilled down to 138 which were then used
in pilot studies between 1976 and 1978 and reduced further to 82. Further work
confirmed that the statements were sensitive to changes over time and to
degrees of disability. The statements were refined conform to the yes/no
format, exclude negative statements and ambiguity, and to conform to a
minimum reading age. Each item was then tested on patients and non-patients
for clarity, prior to a series of validation studies. These were on more than ten
different groups of patients and healthy subjects, comprising over 5000
altogether. Reliability studies on two groups, one with peripheral vascular
disease and the other with osteoarthritis, confirmed a high degree of test-retest
reliability in chronic disease. Following this, different weighting was given to
each statement using Thurstane's Method of Paired Comparisons, although this
approach has since been criticised as inappropriate and leading to logically
inconsistent results: eg. "I can only walk about indoors" (weight 11.54) plus "I
have trouble getting up and down steps" (weight 10.79) outweigh "I'm unable to
walk at all" (weight 21.30) (Jenkinson, 1991). Norms for various differing
patient populations were developed, validation studies performed and the
instrument has achieved a high level of acceptance in the intervening years. It
has been used in many different languages, and validated in such diverse
situations as the measurement of psychological disturbance in unemployed
males, outcome following coronary artery surgery and results of total knee
replacement.
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The General Health Questionnaire, developed by Professor David
Goldberg of Manchester University, was designed to "discover those features
which distinguished psychiatric patients as a class from individuals in the
community who considered themselves to be healthy". Items were gathered
from interviews conducted by Veroff, Feld and Gurin (1962) with 542 non-
hospitalised Americans, covering areas od "adjustment" and "felt distress", and
factor analysis produced the following factors: "felt psychological disturbance,
unhappiness, social inadequacy and lack of identity", which were then used to
select items with high "saturation" of these factors. Items were drawn from
other sources and from psychiatric colleagues. An extensive validation process
included experimentation with format, which was eventually deecided upon as
a four-option response to a statement, but not scored as a Likert-type scale (i.e.
0-1-2-3), but rather as a bimodal response (0-0-1-1). The score for each item
is added to produce a total score. Several different lengths of questionnaire
were developed in parallel and extensively validated in studies on hundreds of
psychiatrically well and unwell subjects. The optimum usage of the instrument
has been in using a threshold total score to indicate individuals in a hitherto
unselected population likely to represent psychiatric "cases". During the past
decade, between 10 and 20 studies every year have added to the data validating
versions of the GHQ in various patient populations.
Linear analogue self-assessment (LASA) had been developed in the 1920s
(Hayes and Patterson, 1921) and during the late 1960s and early 1970s was used
to measure subjective responses in a variety of conditions including rheumatoid
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arthritis, mental alertness and sedative effects in drug trials, (Bond and Lader,
1974). The principle is that the subject is presented with opposite extreme
options of a symptom or item, spaced by a 10 cm line, on which they are asked
to draw a vertical stroke at the point which approximates to how they feel. The
length of line at the point of bisection is then measured. Bond and Lader (1974)
were able to validate the technique in 500 patients, although were of the opinion
that test-retest reproducability may be unstable in their particular patient
population. This may, however, be a more general problem, as it is difficult for
patients, on retesting, to remember exactly where a mark was made previously
on a line. More so than, say, to remember the wording of a response previously
chosen in answer to an item. Priestman and Baum (1976) used LASA in their
early experiment measuring QoL in breast cancer patients, and as late on as
1988, evidence was still accruing that the LASA compared favourably in terms
of validity with other QoL instruments (Boyd et al., 1988).
The Hospital Anxiety and Depression Scale (Zigmond and Snaith, 1983) is
a younger instrument than those mentioned above and has, therefore, not
undergone the same extent of validation. It was developed as a means of
identifying individuals, in a hospital population, suffering from recognisable
psychiatric morbidity. It has been through a similar process of validation prior
to its release, but up until the late 1980s, only a few studies had employed the
instrument. It has the inherent advantage of being simple to use, occupying one
side of A4 paper, and being easy to score on a Likert scale of 0-3. It is easily
disaggregated into the components of Anxiety and Depression, and is perhaps
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more typical of the newer instruments emerging, in that some attention to
presentation and "user-friendliness" has made it an attractive instrument to use.
A problem for those considering QoL measurement for the first time is
the absence of good information on how to process the enormous amount of data
which accrue from QoL measurement. This contrasts with the extensive
theoretical information about the relative merits of various constructs and
weighting systems. In some of the earlier studies, data were analysed by
parametric methods (Priestman and Baum, 1976) or were transformed
logarithmically (Bond and Lader, 1974). In large studies, data may be normally
distributed, but in recent years, as non-parametric statistical methods have also
become more familiar, these have tended to be adopted as the "safest" way of
handling data which cannot be regarded as normally distributed, especially if in
small numbers. The appropriate statistical tests (Mann-Whitney, Wilcoxon,
Kruskal-Wallis, Friedman) are simple and available in many readable books
(Siegel, 1956; Swinscow, 1980; Gardner and Altman, 1990; Brown and Beck, 1989)
and on many computer programs (Minitab, Systat).
Generally speaking, commonsense should prevail (Cox et al., 1992).
Measurements over time should be made against a baseline measurement for
that patient. It should be remembered that confounding factors other than the
construct under examination may also contrive to affect a change in QoL scores
over time (eg a recent bereavement in a patient being tested for perioperative
anxiety) so in general, unless group numbers are large, multiple measurements
should be made over time. In their seminal paper, Fayers and Jones described
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in detail certain principles of QoL data analysis but dwell little upon the
statistical methods in use (Fayers and Jones, 1983).
1.6 When to consider quality of life measurement
QoL measurement was originally developed in order to assess treatment
strategies which could not be assessed accurately in any other way. It can be
applied on an individual level, but is more usually applied to groups of subjects.
As in other studies, this has evolved into two main branches: cohort studies and
controlled studies. In the former, including the quick dirty experiment of the
Baconian variety, to obtain qualitative rather than quantitative information
(Medawar, 1979), a pretreatment score is compared to a single post-treatment
score, or series of scores. In the latter, the change in scores over time is
compared for two or more treatment groups, commonly in the context of
randomised trials designed and conducted in the usual manner.
A growing number of trials reported in the literature have incorporated
some element of QoL measurement. This probably has more to do with the
changing influence of social values on the medical profession than a sudden
increase in new treatments or technologies. Between 1966 and 1970, four
papers had QoL in the title. In the next five years there were 33 papers
(Spitzer, 1987). In 1980, Mosteller et al. reported that of 132 trials in cancer,
the overwhelming majority reported outcome only in terms of survival or
recurrence (Mosteller et al., 1980). Bardelli and Saracci reviewed cancer trials
from 1956 to 1976 and found that in fewer than 5% was QoL measured and that
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even then, objective functional measures such as the Karnofsky and Zubrod
(Zubrod et al., 1960) rather than subjective QoL measures were used (Bardelli
and Saracci, 1978). Now, in the early 1990s, QoL has been a separate keyword
in the Index Medicus for 15 years. Yet, of all the publications in which QoL is
mentioned, only in a small minority is it actually measured.
Amongst the earliest attempts to use patient-derived QoL data was the
study by Priestman and Baum who reported the use of linear analogue self-
assessment (LASA) to measure QoL in breast cancer chemotherapy patients.
They demonstrated that a reduction in tumour size was associated with
improved QoL scores (Priestman and Baum, 1976). QoL measurement has
developed in a variety of conditions other than cancer during the 1980s,
including hypertension (Bulpitt and Fletcher, 1985), inflammatory bowel disease
(Guyatt et al., 1989) and rheumatic diseases (Liang and Robb-Nicholson, 1987).
1.7 Quality of life as a measure of utility
Another area of confusion to the casual reader of QoL literature is the
use of QoL as a measure of utility. This area accounts, at least in part, for the
increased interest in the subject and represents the attempts being made to find
a common currency with which to compare, and ultimately cost, different health
states and treatment interventions. One of the pioneers in this field is George
Torrance, who developed the model of the "quality adjusted life year" (QALY)
(Torrance, 1976). He uses a model of health/time, applying to health care the
analysis of cost-effectiveness and cost-utility (Torrance, 1987). The
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denominator is a Year; the numerator is a number between 0, which represents
death and 1, which represents a state of optimum health. Torrance is careful
to point out that in this model, QoL is health related- that is, without the
social or "beyond the skin" considerations which are included in other QoL
constructs. Torrance defines utility as "a cardinal measure of the strength of
one's preference" and derives his use of the term from the Utility Theory model
for decision making in the face of uncertainty (Holloway, 1979). The utilities
are measured for various states of disease or health in two ways: as determined
by patients actually in that state and hypothetically, by observers, who have
experience of dealing with that health state. Torrance proposes that the
resulting numbers, or QALYs be used in three ways: in clinical decision making,
in group comparisons and in health policy formulation. The principle was seized
upon by health economists at an early stage, but application of the utility theory
to real life has resulted in some perverse consequences. For example, in the
famous, or infamous "Oregon experiment", in response to severe rationing of
resources, an attempt has been made to put medical services in some objective
order of priority. Using the QALY approach, local citizens were canvassed in
a telephone questionnaire using various trade-offs to rank some 2000 conditions
in order of priority. Cosmetic breast surgery was ranked higher than treatment
for a compound femoral fracture, casting doubt on the whole ranking process
(Klein, 1991). Later in the same paper, Klein argues that:
"Technical exercises may be a useful way of starting up the dialogue and
providing statistical scaffolding that may subsequently be dismantled, but they
cannot resolve conflicts of values or interests".
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Harris goes further, arguing that QALYs are unjust because they value time
lived instead of individual lives and take an excessively narrow view of what
QoL might be; he invites the question "is murdering someone with more QALYs
worse than killing someone with fewer?" (Harris, 1988).
1.8 Quality of life measurement in surgery
So what has been happening in surgery and how does the surgeon stand in
relation to the QoL research that developed in the last two decades? In 1987
it was reported that only 3% of trials reported in surgical journals mentioned
QoL (O'Young J and McPeek B, 1987). Four years later, there has been some
progress, although QoL studies have yet to become firmly established in surgical
journals. In 1991, no study reported in the British Journal of Surgery contained
QoL measurement of any description, even though several would have uncovered
clinically relevant information by doing so. Why should this be, especially when
the practice of audit has been deeply rooted in many surgical centres and is set
to become established in many more?
The assessment of medical intervention, referred to as medical audit, has
three components- structure, process and outcome (Donabedian, 1980b). The
measurement of surgical interventions dwells almost exclusively upon the last-
outcome. Surgical outcome is traditionally evaluated according to two basic,
measurable parameters- mortality and morbidity. The latter can be broken
down into several components- operation time, re-operation rate, haemorrhage,
wound healing, infection and readmission. Most surgeons have found that these
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measures, together with the informal and variable feedback on functional
results, accorded by the doctor-patient encounter in the outpatient clinic, give
all the information needed with which to audit their practice. Bunker and
Wennberg drew attention to the inappropriateness of using mortality data to
measure certain aspects of surgery:
"It is to the improvement in the quality of life- to the relief of disability,
discomfort and disfigurement that elective surgery is primarily directed"
(Bunker and Wennberg, 1973).
Ebbs et al. cited the example of appendicectomy as an instance where QoL
measurement would be superfluous: there is only one treatment: the patient has
an appendicectomy and gets better (Ebbs et al., 1989a). However, the advent
of laparoscopic surgery has made even this a debatable assertion.
Goligher acknowledged that:
"Surgeons are often accused of adopting too simplistic an approach to the
outcome of their handiwork, and of being all too frequently content to judge the
results in terms of operative mortality, immediate operative morbidity and, in
the case of operations for malignant disease, the length of survival".
He advocated the use of operation specific assessments using a specially
formulated and searching questionnaire (Goligher, 1987). One of the first
surgeons to attempt measurement of the functional results of operation was
Visick, who conceded that adverse results may arise from gastric surgery and
so devised a simple scale with which to take account of postoperative function
(Visick, 1948). It was Goligher et al., in the first randomised studies by
surgeons, who used this scale to assess their results (Goligher et al., 1968). In
the period since this important study, Goligher was to use this approach to
assess function as a measure of the outcome of surgery to other operations.
Other surgeons have sought to measure the effect of different treatment
modalities using techniques which include psychological assessment- by observer
and by self-assessment scales. In the study by Priestman and Baum on patients
with advanced breast cancer receiving chemotherapy, they developed their own
instrument, the LASA (Priestman and Baum, 1976). The adverse psychological
consequences of mastectomy were reported by Morris et al. (1977) and the
following year by Maguire et al. (1978). However, in a prospective study of 101
patients randomised to receive mastectomy or breast conserving surgery,
detailed psychological QoL measurement by a trained interviewer established
that morbidity was equally high in both groups, most probably as a result of the
cancer itself (Fallowfield et al., 1986). The same year, the psychological impact
of post-mastectomy chemotherapy was reported (Hughson et al., 1986). The
same group reported no difference in psychiatric morbidity conferred by
postoperative radiotherapy (Hughson et al., 1987). In these three studies,
psychological assessment was done using both a trained interviewer and
questionnaires- the Hospital Anxiety and Depression scale (or its
precursor)(Zigmond and Snaith, 1983) in all 3, the Rotterdam symptom checklist
(Pruyn et al., 1981) in the first and the General Health Questionnaire (Goldberg,
1979) in the other two. In 1988, Koivukangas and Koivukangas reported their
study into the QoL of patients undergoing surgery for infiltrative brain tumours.
They started using simply the Karnofsky scale (Karnofsky and Burchenal, 1949)
and the Glasgow Outcome Score (Jennett, 1986) but went on to develop their
own scale, using a multidimensional approach based mainly on semi-structured
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interviews repeated at intervals from before treatment (Koivukangas and
Koivukangas, 1988).
One of the most influential surgeons to promote the role of QoL
measurement in surgical practice has been Hans Troidl who said:
"It is a curious paradox that research reports on the effectiveness of surgery
focus on mortality, length of hospital stay, major complications and laboratory
analyses, when the principle criteria guiding surgeons' clinical decisions are
most often the patients' subjective feelings and physical capabilities, on the
quality of life."
He cited the examples of inguinal hernia repair and oesophageal surgery for
symptomatic reflux as operations undertaken to improve QoL. Whilst he
acknowledged the role of the surgeon's conscious and unconscious estimation of
a patient's QoL before and after surgery, he stated the urgent need for better
techniques to allow surgeons to measure QoL in a simple and practical way
(Troidl et al., 1987). He used this approach to assess outcome in gastric cancer
patients having total gastrectomy and either oesophagojejunostomy or
construction of a Hunt-Lawrence-Rodino pouch. As well as designing a specific
questionnaire, he used a modified version of the Visick scale, as well as general
QoL measures such as the Spitzer QoL index (Spitzer et al., 1981). He
advocates the use of specifically designed questionnaires to assess the precise
outcome of operation, together with more general QoL measures to answer the
question "How are you?" This approach has been advocated independently by
Aaronson (1988) and Ware (1989).
Perhaps the most significant impediment to the acceptance of QoL
measurement as a bona fide branch of research was vividly described by
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Feinstein: namely that it is regarded as "soft science" by those who are used to
measuring phenomena in laboratory conditions (Feinstein, 1977). He describes
the science of "clinimetrics": arbitrary ratings, scales, indexes, instruments or
other expressions that have been created as "measurements" for clinical
phenomena that cannot be measured in the customary dimensions of laboratory
data (Feinstein, 1987a). As examples, he cites the Glasgow Coma Scale
(Teasdale and Jennett, 1974), the Apgar score (Apgar, 1953), the TNM staging
system (American Joint Committee for Cancer, 1977) and the Visick scale
(Visick, 1948)(Feinstein, 1987b). Troidl pointed out the value in terms of
improved surgical practice that the Visick scale, a simple measure with a weak
methodological background, has produced. He later observed: "Clinicians prefer
so-called hard data, even when they are totally irrelevant in measuring the
outcome of a patient, and they ignore the so-called soft data, like pain, fatigue
and quality of life" (Troidl, 1991).
Even traditional gold standards such as Dukes staging for colorectal cancer can
be heavily observer-dependent and subject to considerable variation.
1.8 Health status measurement in surgical practice
There is now a great incentive for surgeons to undertake detailed
measurement of the effect of their work upon individual patients and upon the
population.
The United Kingdom National Health Service reorganisation with the
purchaser-provider split and the introduction of medical audit has focused this.
Health economists are now scrutinising every aspect of surgical provision.
Surgical Audit, hitherto done at the discretion and the pace of the individual
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surgeon, is now being established with specific funds allocated from regional
health budgets. But, in order to develop this, better measures of outcome and
process must be found. If surgeons need to measure their practice more
accurately, they need to know more about the instruments which may help them
with this task.
1.10 Hypothesis: Health status measures, scientifically applied, provide
important additional information to the surgeon.
QoL measures have been used in four main contexts: comparing two or
more treatment interventions in a clinical trial, measuring the health of
populations, determining treatment strategies for the individual patient and
assessing the benefit of alternative uses of resources (Cox et ah, 1992). A
broadly based enquiry was chosen because of the uncertain role of health status
measurement in relation to surgery, and to replicate as nearly as possible the
conditions in which a surgeon might wish to conduct research using health status
measurement. In order to test the hypothesis it was therefore necessary to
apply a variety of techniques to different patient populations, with a variety of
objectives for QoL measurement. It was necessary to adapt techniques and
instruments which have been established in other disciplines. The goal was to
gain wide practical experience of QoL measurement, the endpoint being to
formulate guidelines for further use of health status measurement in surgical
practice. The models were chosen in common conditions, in three areas in
which the author had the most ready access to clinical experience. The first
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three of the four broad contexts were studied: the assessment of alternative
uses of resources was not addressed, other than in specific areas relevant to
each separate study. In each of the studies, the overlap in QoL measurement
ojectives is discussed in the final chapter.
1.10.1 Evaluation of treatments in a clinical trial
The first study entailed QoL measurement in patients with advanced
breast cancer undergoing chemotherapy. This is an area in which perhaps the
most experience of QoL measurement has been reported hitherto. It was
considered appropriate to include this subject in a dissertation on health status
measurement in surgical practice, because there is, as yet, no consensus as to
when to offer chemotherapy to patients who develop advanced breast cancer and
the decision is often made by surgeons. The view of some surgeons who do not
favour chemotherapy for advanced disease is that the distress of chemotherapy
is unwarranted where no survival advantage is anticipated. In many centres, the
surgeon also administers the chemotherapy; the argument against chemotherapy
in advanced breast cancer patients may be reinforced where the anticipated
increase in workload involved in giving chemotherapy is not perceived by the
surgeon to benefit the patient in any obvious or measurable way. Amongst those
who are convinced of its worth, there is still significant doubt as to the optimum
type of treatment to be offered to these patients. Yet at the same time there
seems to be considerable, though not overtly expressed, resistance to the
concept of QoL measurement as judged by the number of trials in which QoL is
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measured.
A study was therefore initiated at King's College Hospital, London and
the William Harvey Hospital, Ashford, Kent in order to investigate the QoL of
patients with advanced breast cancer receiving an aggressive chemotherapy
regimen and those receiving a mild regimen, using well validated instruments
in addition to the traditional recordings of response, toxicity and survival.
1.10.2 Validation of a new QoL instrument
In addition validation was undertaken of a new QoL instrument designed
specifically for such trials in the Department of Surgery at King's College
Hospital. This aspect of the study was augmented by data from a trial of
different chemotherapy regimens at Guy's Hospital, London to allow comparison
of the instrument between studies.
1.10.3 Measuring quality of life to establish a difference in patient populations
The second study is of patients admitted with acute abdominal pain, a
subject extensively discussed in the literature. It has been suggested that
psychosocial factors are influential in the presentation of patients whose pain
will subsequently resolve undiagnosed. This was therefore investigated
prospectively at the William Harvey Hospital, Ashford, Kent using validated
psychological health status questionnaires and clinical assessment.
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1.10.4 Measuring the result of surgical treatment in individual patients
The final study was prompted by the debate surrounding waiting lists for
minor surgery, or even removal of minor surgical procedures from NHS waiting
lists. A prospective study was undertaken in order to determine whether the
results of such treatment can be assessed using QoL measurement prospectively
and whether, in individual patients, different outcomes can be detected.
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CHAPTER TWO
Aggressive or mild chemotherapy for advanced breast cancer? CMF versus
Epirubicin measuring quality of life with three different instruments
2.1 Summary
Forty patients with advanced breast cancer, randomised to receive CMF
or weekly low dose Epirubicin, were evaluated by UICC criteria of response and
WHO toxicity criteria, in addition to three QoL instruments: the "Qualitator"
daily diary card, monthly Nottingham Health Profile (NHP) and Linear Analogue
Self-Assessment (LASA). Response rates were 58% for CMF and 29% for
O
epirubicin (x =3.51,ldf,p>0.05). Median time to treatment failure was 24 weeks
for CMF, 7 weeks for epirubicin (p<0.05) but survival was similar in both groups.
Survival was better for responders than for non-responders (medians 87 and 30
weeks, p=0.02). CMF caused more objective alopecia (p<0.001), nausea and
vomiting (p<0.001) and haematological toxicity (p<0.02). However, QoL
measures only recorded a significant difference in energy and pain, influenced
primarily by the non-responders in each treatment group but with no difference
in overall global scores. Scores for responders, irrespective of treatment, were
better to start with (LASA p=0.001); at three months scores had improved
(Qualitator p=0.021; NHP p=0.041). Scores in non-responders showed no change.
In this small study aggressive chemotherapy gave better response and survival
without impairing Quality of life overall. Detailed QoL measurement should be
integral to all cancer chemotherapy trials.
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2.2 Introduction
The treatment of patients with advanced breast cancer using combination
chemotherapy can cause significant toxicity without greatly prolonging survival
(Powles et al., 1980: A'Hern et al., 1988). Recently, studies have been reported
in which low-toxicity regimens (single agent or short term) have achieved
palliation without affecting survival (Chlebowski et al., 1989; Harris et al.,
1990). For example, Jones has reported a response rate of 43% with Epirubicin
given with a weekly dose of approximately 20mg. No significant
myelosuppression, and minimal nausea and alopecia resulted (Jones, 1988).
Further studies have shown no improvement in response rates by doubling the
weekly dose from 20 to 40mg. There was, however, a considerable increase in
toxicity (Ebbs et al., 1989).
There is a danger that such low toxicity regimens may be accepted
without adequate comparison with conventional combination cytotoxics. One
of the most widely used regimens in advanced breast cancer is the standard
Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF) treatment which
achieves response rates of up to 60% (Bonadonna et al., 1983). This was
therefore chosen as the control arm of a direct comparison with low-dose
weekly epirubicin. As reduced toxicity was central to the development of the




1 Comparison of Epirubicin with CMF using conventional criteria
2 Comparison of Epirubicin with CMF using QoL measures
3 Assessment of QoL measurement as a suitable way of measuring the
results of chemotherapy
2.4 Patients and methods
2.4.1 Patients
Between October 1988 and December 1989, forty patients with advanced
breast cancer attending the Breast clinics at King's College Hospital and the
William Harvey Hospital were randomised to receive CMF or Epirubicin as first
line chemotherapy. Criteria for inclusion were: histologically proven locally
advanced disease, rapidly progressing primary disease, metastatic disease failing
to respond to hormonal measures, a first recurrence which was visceral, or
recurrent disease less than 2 years from primary treatment. Excluded, were
postmenopausal women with locally advanced disease suitable for a trial of
tamoxifen, those with a significant medical condition or known previous or
current cardiovascular disease and patients who had received non-adjuvant
chemotherapy. The two groups were evenly matched according to the sites of
disease, and menopausal status, although there was a difference in their median




Median Age 52 (26-80) 63 (39-84)
Premenopausal 9 4
Postmenopausal 12 15





QoL: NHP 129 91
LASA 53.5 35
Qualitator 64 75
Table 2.1: Characteristics of patients recruited to the CMF/Epirubicin trial,
including sites of disease and initial quality of life scores
2.4.2 Ethical considerations
The trial was approved by the ethical committees in both participating
hospitals. Written informed consent was obtained from the patients prior to
randomisation.
2.4.3 Treatment
All therapy was given in the outpatient clinics by one person. The dose
schedules were: 1) Epirubicin 20mg intravenously, given into fast-running 0.9%
O
saline every 7 days. 2) Cyclophosphamide lOOmg/m orally on days 1-14,
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Methotrexate 35mg/m intravenously on days 1 and 8 and 5-fluorouracil
O
600mg/m intravenously on days 1 and 8, on a 28 day cycle. Anti-emetics were
given parenterally or orally as appropriate. In practice, intravenous
Metaclopramide lOmg was given prophylactically to every patient receiving
CMF at the time of cytotoxic administration and Prochloperazine in tablet or
suppository form was given on request to patients to take at home. Dose
reductions were made for patients over 65 years old and dose modifications
made if the WBC fell below 3000/1^ or platelets to below 100/1^. One patient
on CMF experienced mucositis for which she was given Calcium Folinate 15mg
every 6 hours for 24 hours.
2.4.4 Assessment of Disease
The endpoints chosen were: Time to treatment failure, survival,
International Union Against Cancer (UICC) response criteria (see Appendix 1),
World Health Organisation (WHO) toxicity criteria (see Appendix 2) and Quality
of Life. Time to treatment failure was defined as the time to progression of
lesions either on measurement or symptomatically requiring addition to or
alteration in therapy, or the abandonment of treatment due to toxicity. If
treatment failure occurred before completion of a six-month course of
treatment, alternative therapy was given as appropriate. After six months,
chemotherapy ceased and no treatment was given until or unless recurrence
occurred or disease progressed. Clinical and laboratory measurements made at
entry to study were a full medical history and examination, weight, height, age,
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date of birth, PMH, full blood count, differential WBC, biochemical screen.
Photographs were taken of visible lesions and records made of tumour
dimensions. All patients had a bone scan, liver ultrasound scan and chest
radiograph. CT scan was performed in patients whose lesions were not
otherwise measurable. Quality of life assessment was made using the
Nottingham Health Profile (Hunt et al., 1885)(see Appendix 3) and Linear
Analogue Self Assessment (Priestman and Baum, 1976)(see Appendix 4) at the
start of treatment and four weekly thereafter; throughout treatment, patients
completed the Qualitator daily diary card (see Appendix 5), a new instrument
developed for breast cancer chemotherapy trials (Fraser et al., 1990)(see
Appendix 13). Full blood count was measured prior to administration of
intravenous cytotoxics. Patient characteristics were compared using the Chi-
squared and t-tests.
2.4.5 Survival and response analysis
UICC criteria of response were assessed monthly. The WHO toxicity
criteria were recorded every four weeks. UICC response rates were compared
using the Chi-squared test and time to treatment failure and survival analyses
were done using the Kaplan-Meier life table method (Kaplan and Meier, 1958)
and log rank test (Peto et al., 1977). Correlation between initial QoL scores and
survival was done using Spearman's rank correlation method.
44
2.4.6 Quality of life analysis
With all instruments, a high score indicates poor QoL. The NHP scores
were analysed as recommended by the authors (Hunt et al., 1976) so that at each
completion, a weighted score out of a possible 100 was obtained for each of the
six components: emotional state, energy, pain, physical mobility, sleep and
social factors. In this study, the components were then added to give a global
score range of 0-600. The LASA questionnaire consisted of 26 categories, each
scored 0-9 on a visual analogue scale. Two categories, the "open" item and the
general statement on QoL were excluded from analysis, as the former was
ignored by most patients and the latter was judged to duplicate the rest of the
questionnaire. The global range was therefore 0-216. Both NHP and LASA were
compared between patient groups at each juncture using the Mann-Whitney-U
test. Comparison with subsequent scores was performed using the Wilcoxon rank
test. Completion of the Qualitator involves the choice of 5 symptoms from a
menu of 23, in 4 domains, scoring on a categorical scale 1-4. The details are
described in chapter three; the range of the weekly global score is from 35-140.
For comparison, pre-treatment NHP and LASA scores were compared with the
first week of the Qualitator and thereafter, the comparison of NHP and LASA
monthly scores was with an average of each patient's aggregated Qualitator
scores for that month. Analysis was then performed using the same non-
parametric methods as for the NHP and LASA. Analysis of individual Qualitator
symptoms is also described in chapter three.
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2.4.7 Exclusions
Forty patients were entered into the trial. Thirty seven patients
completed the NHP and 36 the LASA at the start of the study. Three exclusions
were patients who were unable to start treatment following randomisation and
subsequently left the study. The other LASA was incorrectly completed by the
fourth patient. Thereafter, patients remaining in the study completed the NHP
and LASA during each month of treatment. Three CMF patients failed to do so
at 1 month and one at 5 months; one patient failed to complete them at 4
months. The Qualitator was commenced by 29 patients. At the start of the
study three elderly patients were, in retrospect mistakenly, not offered the
Qualitator. One patient, once randomised refused to complete it, one
progressed rapidly after 1 month and was unable to return the card. The
remaining six patients progressed rapidly within a week of the start of
treatment and were also unable to return the diary cards.
2.5 Results
2.5.1 UICC response
The response rates according to UICC criteria were 58% for the CMF
group and 29% for the Epirubicin group (x2=3.51,ldf, p>0.05, see Table 2.2).
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UICC Response CMF Epirubicin
Complete 1 0
Partial 10 6
No change 2 7
Progression 3 5
Rapid progression 3 3
Table 2.2: UICC response of patients according to treatment randomisation
If the six patients who relapsed before or within the first week of
treatment are excluded as in other studies the difference is significant
o
(x =4.30,ldf,p<0.05). The time to treatment failure was longer for CMF
patients than Epirubicin patients: medians 24 weeks and 7 weeks (X =5.17,ldf,
p<0.05, see figure 2.1).
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Time since start of treatment [days)
Figure 2.1: Life table indicating time to treatment failure. Patients grouped
according to allotted treatment (Epirubicin n=21, CMF n=19)
Survival was similar in both treatment groups: medians 57 weeks and 55
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Figure 2.2: Life table indicating overall survival. Patients grouped according
to allotted treatment (Epirubicin n=21, CMF n=19)
UICC responders, as expected from many previous studies (A'Hern et al.,
1988) survived longer than that non-responders: medians 87 weeks and 30 weeks
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Figure 2.3: Life table indicating overall survival. Patients grouped according
to UICC response (No response n=23, Response n=17)
Toxicity was very low for all patients receiving Epirubicin. CMF caused
significantly more alopecia (p<0.001), nausea and vomiting (p<0.001) and
haematological toxicity (p<0.02) above WHO grades I (see Table 2.3). One CMF
patient required hospital admission for treatment of septicaemia. One
Epirubicin patient receiving prednisolone for scleroderma developed septicaemia
requiring hospital admission. There were no fatalities due to side-effects of
treatment.
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Epirubicin 83 0 75(90) 83(100) 82(99)
1 8(10) 0 0
2 0 0 0
3/4 0 0 1(1)
CMF 106 0 43(41) 64(60) 75(71)
1 20(19) 22(21) 20(19)







Table 2.3: Toxicity according to WHO grade: number (%) of each treatment
group in each toxicity category, on each month
2.5.2 Quality of life at entry to the trial
The respective NHP, LASA and equivalent aggregated weekly Qualitator
scores were compared for each month. Patients' QoL scores were analysed
according to response and to treatment. Prior to the start of treatment, a
poorer QoL was recorded amongst patients who subsequently did not respond,
statistically significant only for the LASA, (p<0.002). The pre-treatment scores
are illustrated in figure 2.4, in which the LASA, NHP and Qualitator scores are
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Figure 2.4: Box plot depicting QoL scores at start of treatment according to
subsequent response. The data for each instrument are arithmetically adjusted
to be comparable on a simplified range of 0-10.
Qual=Qualitator, NHP=Nottingham Health ProfHe, LASA=LinearAnalogue Self-
Assessment, Res=Response, No R=No Response.
For key to interpretation of box plots used in this thesis, please refer to
Appendix 6.
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Patients' Qol scores at the start of the study were correlated by rank
with their subsequent survival. The Spearman co-efficients were -0.52 (95%
c.i.-0.72,-0.23) for the LASA, -0.35(-0.60,0.04) for the NHP, -0.64(-0.82, -0.36)
for the Qualitator.
2.5.3 Quality of life during treatment
Compliance for the 29 patients who started the Qualitator, the 37 who
started the NHP and 36 who started the LASA respectively were 88%, 89% and
92%. Figure 2.5 shows the mean global QoL values in each treatment group at
each stage for all patients remaining in the study. The means are used purely
for graphic representation: statistical comparison between treatment groups was
by a rank test at each month.
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Months
Figure 2.5: Mean QoL scores at each month of treatment for Epirubicin
patientsf ) and CMFpatients(.....) for each of the three QoL instruments
used. The data for each instrument are arithmetically adjusted to be comparable
on a simplified range of 0-10.
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Table 2.4 shows the median improvement in QoL score for the 29 patients
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1.95 0.1 12.5 -41.5 -23.8 17 -4 -5 0.5
Table 2.4: Median improvement in QoL score for all patients completing each
questionnaire during first 3 months of study (compare Table 2.6)
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Figures 2.6,2.7,2.8: The change in QoL
scores in patients who responded:
At 1 week and 12 weeks for
Qualitator (15 patients)
the
Before treatment and at 3months for the
Nottingham Health Profile (17 patients)
and Linear Analogue Self-Assessment (17
patients)
The data for each instrument are
arithmetically adjusted to be comparable
on a simplified range of 0-10.
o
CMF 0 CMF 3 Epi 0 Epi 3
LASA
Non-responders experienced no significant difference in their initial
scores and the final scores prior to treatment failure: Qualitator medians 80 to
74 (p=0.5), NHP medians 133 to 182 (p=0.435), LASA medians 64 to 71 (p=0.55).
The pre-treatment difference in scores between responders and non-responders
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persisted on each monthly comparison: one month (LASA p<0.02, NHP p<0.01,
Qualitator p<0.05), 2 months (Qualitator p<0.05) 3 months (NHP p<0.05,
Qualitator p<0.01) and 4 months (NHP p<0.05).
All of the QoL measures allow sub-analysis in considerable detail. In
separate analysis of the six components of the NHP (emotional state, energy,
pain, physical mobility, sleep and social factors) and the LASA symptoms in four
sub-groups (physical symptoms, social factors, psychological factors and physical
performance), non-responders had worse scores, significantly at most stages
except for the NHP emotional state and energy. The only significant difference
was a better score in CMF than Epirubicin patients in the NHP score for pain
at 2 months (median 9.5, p<0.05), energy at 3 months (median 24, p<0.05) and
a worse Qualitator score at 3 months for personal relationships in CMF patients
(median 0.65, p<0.05). In each case the high scores were amongst the non-
responders in each group.
2.6 Discussion
One of the most difficult decisions facing clinicians treating patients
with advanced breast cancer is what to do when second line hormone therapy
fails. At what point does one advise chemotherapy, to whom and how
aggressively? Until recent years, the success of a treatment regimen has been
defined almost solely by tumour shrinkage. Although toxic side effects have
been measured, there was little evidence of correlation with the patient's
experience. The failure of many studies to show a survival advantage to any
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regimen caused some clinicians to question the merits of giving chemotherapy
at all (Powles et al., 1980). During the last decades, the concept of Quality of
Life has become increasingly important in those patients in whom little survival
advantage is anticipated through treatment and efforts were made to define and
measure it (Fallowfield, 1990). Increasing numbers, but still a minority, of
studies measure QoL (Byrne, 1992). The disparate instruments and periods of
measurement have made it difficult to interpret how chemotherapy affects QoL
for patients with advanced breast cancer. The aim of this study was to compare
a standard combination regimen with a single agent regimen in which different
toxicity and possibly different response rates could be anticipated, and whether
a difference in survival or QoL would result. Detailed intermittent QoL
measurement was made with three instruments, two of which were specifically
designed for the task. The response data were consistent with previous studies
in that the patients who had a measurable response enjoyed longer overall
survival. Although survival amongst patients with non-progressive disease was
better for CMF patients, the poor survival of CMF non-responders was enough
to redress this balance so that survival for the two treatment groups as a whole
was equal. Few studies are large enough to show a survival difference between
treatment groups, but A'Hern et al. showed that a better response rate equated
with longer median survival in a statistical overview of 50 chemotherapy trials
(A'Hern et al., 1988).
The QoL data were not wholly expected. Although Ebbs et al. (1988) had
reported that good pre-treatment QoL scores were associated with a subsequent
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response, we found that there was a close correlation with subsequent duration
of survival too. Morris and Sherwood (1987) described this in terminally ill
patients, and Addington-Hall et al. (1990) used the Spitzer QoL Index (Spitzer
et al., 1981) to predict duration of survival in 230 terminally ill patients.
However, it was a surprise that even in this small study, such a consistent trend
would emerge. In the context of patients with advanced breast cancer, this may
be of significance in deciding on treatment.
Low objective toxicity in patients treated with Epirubicin was reflected
in the recording of specific treatment-related symptoms in the Qualitator, but
QoL scores overall were unaffected and resembled closely the global scores of
the other two instruments. QoL improved for responders in both groups from
the start of the study onwards but did not alter for non-responders.
Is a harsher regimen therefore the treatment of choice for advanced
breast cancer? The evidence is that it does not impair QoL in non-responders
of whom there are fewer anyway and QoL improves for responders. A similar
conclusion was drawn by Coates et al. (1987) who found that Quality of Life
declined significantly in patients on the less aggressive regimen, in which
response was poorer. Moreover, Slevin et al. (1990) found cancer patients much
more willing to contemplate radical chemotherapy than were their doctors for
them. However, if pre-treatment QoL scores give not only a guide to response,
but to survival as well, then perhaps those patients with clinically advanced
disease in whom QoL is poor, who will not respond and whose survival will be
poor should not be given chemotherapy at all. A different interpretation of
59
these findings might be that those patients whose disease is not yet advanced
enough to affect their QoL are those most likely to respond to treatment; one
could go further, and suggest that a prolongation in survival is independent of
any effect afforded by treatment. Therefore, QoL measurement should be used
to help define a treatment strategy, early on in the advanced disease.
One way of resolving the difficulty would be to involve the patient more
fully in the decision-making process. This is an approach which has recently
been advocated by Wennberg in the United States. He and colleagues are
conducting pilot experiments into interactive videotapes on early breast cancer
treatment in Hanover, New Hampshire (Wall Street Journal, 1992). A study in
which the findings also support this approach was reported in the New England
Journal of Medicine by Cassileth et al. (1991). Patients with metastatic cancer
of bowel, lung, pancreas or melanoma, who received conventional therapy,
including chemotherapy, had no better survival than matched controls having
"alternative" therapy. Chemotherapy was not associated with a worse QoL, and
although the change in QoL was similar in both groups, the patients treated
conventionally started and finished with better QoL measurement. The authors
suggested that this may be accounted for by a difference in the social
composition of the groups: a higher number of alternative therapy patients had
degrees and it may have been that poor QoL contributed to the decision to seek
unproven therapy. They concluded that the ideal study in such patients would
be randomised, with a no-treatment arm involving only palliative care.
The present study does not provide solutions to these uncertainties.
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However, detailed QoL measurement is shown to add valuable and perhaps not
wholly expected information in evaluating advanced breast cancer
chemotherapy. If nothing else, measurement of QoL would constitute a cheaper
alternative trial endpoint to the battery of tests required to fulfil UICC criteria
of response. There is a compelling case for inclusion of QoL measurement in
all protocols. Only thereby will knowledge of QoL measurement accrue and its
precise role in the clinical decision making process become clear.
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CHAPTER THREE
Validation of the Qualitator daily diary for quality of life measurement in
advanced breast cancer trials
3.1 Summary
The Qualitator daily diary card, mentioned in chapter two, was designed to
measure Quality of Life in chemotherapy trials for patients with advanced
breast cancer. In addition to the trial at King's College Hospital and the
William Harvey Hospital in which 29 patients completed the Qualitator, 31
patients completed the precursor diary card to the qualitator in a separate study
at Guy's Hospital. The Qualitator offers accurate prognostic data regarding
subsequent UICC response and survival and is simple to use.
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3.2 Introduction
The use of combination cytotoxic chemotherapy as palliation for patients
with advanced breast cancer became established in the late 1960s (Cooper et
al., 1969). Few trials show a survival advantage for a particular regimen and
only recently has an overall improvement in survival been associated with
treatments giving higher response rates (A'Hern et al., 1988). Although the aim
of treatment is to improve the Quality of Life of the patient, regimens are still
compared on the basis of their response rate in patients where such
measurements can be made. Side effects of chemotherapy such as alopecia,
vomiting and lethargy are assumed to affect the QoL of the patients, but their
objective measurement is a secondary aspect in most trials. Subjective, patient
derived, measurements are seldom made.
The simple technique of QoL measurement using the patients' subjective
symptoms using visual analogue scales was adapted for use in breast cancer
patients by Priestman and Baum (1976). They reported a significant
improvement in QoL scores in patients whose tumour area reduced (Baum et al.,
1980). The method has since been well validated (Boyd et al., 1988). Since
then, QoL measurement in cancer patients has been advocated widely (Maguire
and Selby, 1989). However, in 1986, Macaulay and Smith reported that in a
review of over 230 advanced breast cancer trials, in only 2 had overall QoL been
measured. They added that assessment of the value of particular treatments
should not rest upon response rate alone (Macaulay and Smith, 1986). So it is
disappointing that during 1991, 15 years after Priestman and Baum's paper was
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written, of 48 studies of chemotherapy in advanced breast cancer listed in the
Index Medicus, we found only one which included QoL measurement. Many
clinicians still prefer to rely upon their clinical judgement, although Slevin et
al. found poor correlation between QoL measured by doctor and by patient
(Slevin et al., 1988). One problem may have been the QoL instruments on offer.
Well-validated instruments did not include items about vomiting, nausea or hair
loss and none was specific to breast cancer or chemotherapy. Moreover, QoL
measurement is labour-intensive. We therefore addressed these problems.
In QoL measurement, a gold standard does not exist nor is it desirable
according to Bergner (1989). Instruments fall into two broad categories:
multidimensional, designed to measure specific aspects of disease or treatment,
and global, which give a single score for as broad a representation of QoL as
possible. The former approach was chosen, to complement existing instruments,
with weighting provided by allowing the patient to choose the items of
relevance to her. To take account of the fluctuations which may be expected
to occur in patients on chemotherapy, a diary format was adopted. Guidelines
proposed in 1986 by Guyatt et al. (1986) were followed. A six stage process
comprises item selection, item reduction, format design, pretesting, construct
and test-retest reliability and finally validation. Items were amassed and
distilled from all the QoL measures then available and others were added after
consultation with a panel which included a psychologist, a surgeon, a GP and a
nurse counsellor. The validation of the "King's Diary" in its preliminary format
was undertaken by Ebbs et al. during a trial comparing Epirubicin in two
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different doses and administration systems, in which thirty nine patients
completed the initial form of the diary during their treatment (Ebbs et al.,
1989b). This development process resulted in the "Qualitator" and has been
described previously (Fraser et al., 1990)(see appendix 13). The validation
process, continued in two separate trials, is described below.
To test the ability of the Qualitator to measure what it is purporting to
measure, it is necessary to consider what is known so far about QoL in advanced
breast cancer patients, and in cancer patients in general. Baum et al. reported
that a response to chemotherapy improved QoL scores, especially for pain and
insomnia (Baum et al., 1980); Ebbs et al. reported that good pre-treatment QoL
scores were associated with a subsequent response (Ebbs et al., 1988). A
relationship between poor QoL and poor survival was reported by Morris and
Sherwood in a study of terminally ill patients (Morris and Sherwood, 1987).
Later, Addington-Hall et al. used the Spitzer QoL Index to predict survival in
230 terminal patients (Addington-Hall et al., 1990).
3.3 Objectives
1 Validation of the Qualitator diary by comparison with different QoL
measures in the Epirubicin and CMF trial
2 Validation of the Qualitator diary by comparison of data from two trials
3 To find a suitable way of analysing diary data
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3.4 Patients and methods
3.4.1 Patients
Data were collected from two different studies, each with two arms.
The first is described in chapter two. Forty patients with advanced breast
cancer attending King's College Hospital and the William Harvey Hospital were
randomised to receive the standard 28 day cycle of CMF (Bonadonna et al.,
1983) or weekly Epirubicin 20mg, for six months or until treatment failure
between October 1988 and March 1990. The baseline Qualitator was completed
by 29 patients who also completed baseline measurements in the Nottingham
Health Profile (NHP)(Hunt et al., 1985)(see appendix 3) and the Linear Analogue
Self-Assessment (LASA)(Priestman and Baum, 1976)(see appendix 4).
Comparisons between the three instruments were made for the 29 patients who
completed them all. QoL measurement was continued for six months but
stopped if disease progressed first.
In the second study, at Guy's Hospital, thirty nine patients were
O p
randomised to receive Adriamycin 25mg/m weekly or 75mg/m three-weekly
to examine the influence of treatment schedule on response, survival and quality
of life. Thirty one patients completed the diary in its preliminary format
between 1986 and 1987, at the commencement of twelve weeks of therapy
(Richards et al., 1992) and continued until treatment was complete unless
disease had progressed first. Data from 60 patients were therefore available for
analysis.
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3.4.2 Administration and scoring of quality of life measures
The Qualitator daily diary card, described briefly in chapter two, is
administered three-weekly and completed continuously from the first day of
treatment (see Appendix 5). From 23 items the patient chooses one she
considers the most important from each of four domains: 1) symptoms of disease
and side effects of treatment, 2) psychological aspects, 3) personal relationships
and 4) physical performance. In addition a weighting variable is chosen from
any domain. Daily thereafter, a score from 1-4 is given to the five chosen
items, corresponding to the severity with which each item is perceived: "Not at
all", "A Little", "Somewhat", "Very Much". The opportunity to change items
occurs every three weeks, when a new card is exchanged for the old one. This
period was chosen to suit the regimens used in the initial study (Ebbs et al.,
1988) and was kept for subsequent studies. Each patient's aggregated daily
score is added to obtain a weekly total in the range 35-140. In both studies,
patient groups (and other QoL measures in the King's study) were compared
using a mean diary score taken from the completed weeks during each
successive four week period. This allowed inclusion of all the available data,
but allowed for any missing weeks. Isolated missing days were given the mean
score for the other days that week.
In the King's study the NHP and LASA were administered prior to
treatment and every four weeks thereafter, before the administration of
chemotherapy and the QoL scores were processed when the study was finished.
As previously mentioned, with all three instruments, a high score indicates poor
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QoL. The NHP gives a weighted score out of 100 for each of six components:
emotional state, energy, pain, physical mobility, sleep and social factors.
Adding the components of the NHP was not part of its original design, but
allows a global comparison, giving a range of 0-600. The LASA consisted of 24
categories, each scored 0-9, producing a global score range of 0-216. For
comparison between instruments, pre-treatment NHP and LASA scores were
compared with the first week of the Qualitator and thereafter, the average
four-weekly Qualitator score.
In both studies, the Mann-Whitney-U test was used to compare the QoL
scores of responders and non-responders each month and to compare initial and
subsequent scores within a patient group. Comparison of QoL scores at each
month of treatment with the first week's score was performed using the
Wilcoxon signed rank test. Survival according to the Qualitator scores during
the first week and the first four weeks of treatment were calculated using the
Kaplan-Meier life table method (Kaplan and Meier, 1958) and the log-rank test
(Peto et al., 1977).
Patterns of three-weekly item choice were tabulated without statistical
analysis. To compare individual items, eg pain, whether chosen in its own
domain or as a weighting item, all patients who ever chose that item during the
course of treatment had that score processed in the same way as the global
scores, giving a range of 7-28. Patients who never chose that item were
excluded from the analysis, but those who had not yet chosen the item, or who
had stopped choosing it, were given the score 0 for purposes of non-parametric
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statistical comparison, making the range for individual items 0-28, the step from
"not yet chosen" or "no longer chosen", to "chosen, but given minimum score"
being deemed a relevant distinction. The further analysis of individual
symptoms is discussed below. Comparison of the global scores between
instruments was performed using Pearson's correlation coefficient.
3.5 Results
3.5.1 Compliance
1) The King's study: The NHP and LASA were completed by all 29
patients who completed the Qualitator, 14 in the CMF arm and 15 in the
Epirubicin arm. Eleven patients did not complete the Qualitator: three elderly
patients were, mistakenly, not asked to do so, one patient refused and the rest
either did not start it due to rapid progression of disease, or were unable to
return the completed card on early progression of disease. The Qualitator was
completed for 419 (88%) out of the total of 474 weeks. The missing weeks were
48(18%) of 262 in the CMF arm compared to 7(3%) of 212 in the Epirubicin arm
O
(x =25.8, p<0.001). One patient preferred not to indicate the item in each
domain which she had chosen so her data were only allowable for numerical
analysis of the global scores. One patient failed to choose a weighting question
for the fifth domain which was not discovered until the end of the study. Her
score was multiplied by 1.25 in order to allow comparison of her global scores.
There were eight isolated missing days. The same 29 patients completed the
NHP and LASA on 104 of the possible 117 occasions, a compliance of 89%.
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2) The Guy's study: The missing weeks were 13(11%) of 123 in the weekly
treatment arm and 46(21%) of 220 in the 3-weekly treatment arm (x =5.92,
p<0.02). Missing weeks were incurred most often as a result of delayed
treatment due to haematological toxicity, and omission of the diary during the
interim recovery period. There were 15 isolated missing days.
3.5.2 Response to treatment
In the King's study, of the 29 patients who completed the Qualitator, 15
(52%) responded clinically. In the Guy's study, 15 (38%) of the original 39
patients responded clinically, 11 (37%) of the 30 patients who completed the
diary.
3.5.3 Quality of life: correlation between instruments
Correlation between the global scores of the individual instruments was
0.78 between the NHP and LASA. Correlation between the Qualitator first
week, and subsequent four week aggregate, scores with the corresponding global
NHP and LASA scores was 0.68 and 0.67 respectively.
3.5.4 Quality of life at entry to trial
Diary scores for the first week of treatment were taken as the baseline
in both the King's and the Guy's trials. Comparison was made between the
scores of patients who subsequently had a response to treatment (UICC) and
those who did not. Taken separately, the King's responders had a median of 60,
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non responders of 80 (p<0.1). Guy's responders had a median score of 43, non-
responders of 81 (p<0.05). Added together, responders from both studies had a
median of 59 and non-responders 81 (p<0.005). A first-week score of below 52
gives the highest odds ratio of a response to treatment, 6.21 (95%c.i. 1.70-22.8).
In the both the King's study and the Guy's study, the first month's mean diary
scores were significantly better for responders: (King's 56 v 73, p<0.05; Guy's
55 v 83, p<0.05). The pre-treatment NHP and LASA scores in the King's study
gave a similar pattern in predicting responders and non-responders: (LASA
responders 22, nonresponders 64, p<0.005; NHP responders 88, non-responders
162, p<0.1). The initial scores of all instruments in the King's study are














Figure 3.1: Box plot depicting QoL scores at the start of treatment for 29
patients who completed all 3 instruments in the King's study. The data for each
instrument are arithmetically adjusted to be comparable on a simplified range
of 0-10.
Qual=Qualitator, NHP=Nottingham Health Profile, LASA=LinearAnalogue Self-
Assessment, R=Response, NR=No Response.
For key to interpretation of box plots used in this thesis, please refer to
Appendix 6.
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To assess the relationship between early Qualitator scores and subsequent
survival, the 60 patients from both studies were divided into high scoring and
low scoring groups of nearly equal size using a threshold score of over 65.
Survival was significantly better for patients with low scores in both the first
week (median survival 57 weeks, 33 weeks; x =5.63,ldf,p<0.02)(see figure 3.2)
and the first 4 weeks (median survival 57 weeks, 30 weeks;
x2=13.14,ldf,p<0.001)(see figure 3.3).
Time since start of treatment (days)
Figure 3.2: Life table indicating survival: patients grouped according to first
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Figure 3.3: Life table indicating survival: patients grouped according to first 4
weeks' Qualitator scores (>65 n=29, 65 or less n-31)
In the King's study, in order to assess the prognostic significance of a
high qualitator score at the start of treatment, comparison was made with other
data documented at the start of treatment in the 29 patients in whom all data
had been recorded (see Table 3.1). This indicates that a Qualitator score over
65 was a more potent indicator of survival than all other factors (see figures 3.4
and 3.5). The LASA also demonstrated a significant difference in the survival
of high scorers and low scorers (see Table 3.1).
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Total x2 P
LASA > 45 14 4.98 0.03
NHP > 100 16 0.70 0.40
Qualitator > 65 15 6.90 0.01
Menopausal 19 0.004 0.95
Site of disease:
Soft tissue 15 3.37 0.07
Nodal 14 0.03 0.86
Bone 13 0.28 0.60
Lung 6 0.13 0.72
Liver 6 4.85 0.03
Table 3.1: Survival differences according to factors recorded in 29 patients at
entry to the King's study. Each factor is used, in turn, to calculate an overall
survival difference using the log-rank method.
Figures 3.4 and 3.5: Life tables indicating survival in 29 patients in the King's
study, grouped according to their first week's Qualitator score, or presence of
liver metastases at start of treatment
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However, if all 40 patients who entered the trial, but did not necessarily
complete QoL measurement, are considered, then the most significant indicator
of poor prognosis was the known presence of liver metastases at entry to the
trial (x^=10.69,ldf,p=0.001).
3.5.5 Quality of life during treatment according to response
The initial difference between the diary scores of responders and non-
responders persisted for three months in the King's study (p<0.05, p<0.05,
p<0.02) and four months in the Guy's study (p<0.05, p<0.05, p<0.05, p<0.05). The
corresponding differences in global scores for the NHP and LASA for the 29
patients in the King's study were not significant after 1 month.
Comparing patients' first week's Qualitator score with the corresponding
aggregated score for one, two and three months, there were significant
improvements for responders in the King's study at two months (median 8.55,
p<0.05) and three months (median 12.5, p<0.01). There was no difference in the
scores of non-responders. In the same patients, a similar pattern was observed
in the NHP responders at three months (median 67.8, p<0.06) though less so in
the LASA (median 1.75, p<0.8). The same trend of improvements in QoL score
were not significant in Guy's responders. In order to illustrate the weekly trend
in QoL scores amongst patients, figure 3.6 shows the mean diary scores in each




Figure 3.6: Mean Qualitator scores during the first 12 weeks of the King's
(. ) and Guy's ( ) studies, grouped according to UICC response
3.5.6 Quality of life during treatment according to therapy
Comparing the change in Qualitator scores, between the first week and
the subsequent aggregated score for one, two and three months, an improvement
was recorded in the King's study for Epirubicin (median 7.2, p<0.02) and CMF
(median 8.93, p<0.02) patients remaining at three months. This pattern was seen
in the NHP score at three months for the same patients on CMF (median 67.75,
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p<0.02). In the Guy's study, patients on the three weekly regimen had improved
Qualitator scores at three months (median 9.4, p<0.05). The King's scores are











-38.5 -7 17.25 10.75 5 9.25
















1.95 0.1 12.5 -35.5 24 37.25 0 5.5 7
Table 3.2: Median improvement in QoL score, from initial measurement, during
first 3 months of study for 29 patients in whom data were available (compare
Table 2.4)
3.5.7 Analysis of separate items and domains
The Qualitator can be sub-analysed in detail but caution has been
exercised to avoid producing spurious results. In Table 3.3, the total number of
3-weekly item choices in each study has been compared. Domain 1 receives
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most of the weighting scores. Pain, tiredness, hair loss, activity and overall
condition are chosen frequently in both studies. One patient out of the 60 in
both studies did not indicate her item choices and 11 progressed or died on
treatment after 3 weeks. Eight who did not change items from the first week
onwards had a total of 42 opportunities to do so and the remaining 40 who did
change had a total of 144 opportunities on which to do so. This opportunity was
exercised, respectively, in groups 1,2,3,4 and the weighting group on 48, 46, 21,
41 and 75 occasions.
Analysis of the separate domains, 1-4, in the King's study demonstrated
no significant improvement in score for any patient group in any domain.
Differences between the scores of responders and non-responders are illustrated
in Table 3.4. In the separate items, in the King's study, the only significant
change was that at 3 months the scores for pain had improved for responders
(medians 15 to 8.25, p<0.02) but not for non-responders (15.25 to 16). A similar,
though non-significant trend was observed in the Guy's study.
Table 3.3 (over page): Relative proportions of Qualitator items chosen
throughout study. In the column marked (%), the figure represents the total
number of three weekly choices, including the weighting choice, made for that
item, expressed as a percentage of the figure that would be obtained by
distributing all choices evenly between each item.
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31 28 27 32
Smp Wt Tot % Smp Wt Tot % % %
Pain 27 4 31 187 57 14 71 292 266 267
Breathing 22 1 23 135 9 5 14 58 89 107
Tired 13 13 26 153 24 32 56 230 155 179
Appetite 11 7 18 106 13 5 18 74 44 107
Feel sick 10 5 15 88 19 10 29 119 111 107
Vomiting 4 4 8 47 0 1 1 4 67 36
Bowel
upset
7 11 18 106 1 5 6 25 44 71
Hair loss 4 16 20 118 23 20 43 177 155 89
Total 99 61 160 940 146 92 238 979 931 963
Anxiety 23 5 28 115 34 1 35 99 123 100
Depress. 28 3 31 127 11 5 16 45 77 87
Sleep 19 3 22 90 74 5 79 224 107 174
Future 17 6 23 94 22 8 30 85 107 112
Life 12 1 13 53 5 0 5 14 61 25
Total 98 18 117 480 146 19 165 467 475 498
Partner 27 1 28 115 41 0 41 116 107 124
Family 39 1 40 164 53 0 53 150 184 149
Friends 6 0 6 25 8 0 8 23 31 12
Sexual 1 0 1 4 1 0 1 3 15 12
Social 23 0 23 107 43 0 43 122 92 112
Total 98 2 101 414 146 0 146 414 429 409
Work 8 1 9 37 14 4 18 51 77 50
Hobbies 2 0 2 8 5 2 7 20 15 0
Activity 40 3 43 176 54 9 63 178 168 149
Overall 25 11 36 148 49 11 60 170 168 124
Self care 23 3 26 107 23 4 27 76 77 149
Total 98 18 116 476 145 30 175 496 505 472
Start Month
1 2 3 4
NHP
Emotional NS NS NS NS NS
Energy NS NS NS NS NS
Pain NS p<0.05 p<0.01 NS NS
Performance <0.05 p<0.05 p<0.05 NS NS
Sleep NS NS NS NS NS
Social isolation p<0.02 p<0.001 NS NS NS
LASA
Physical Symptoms p<0.01 p<0.05 NS NS p<0.05
Emotional p<0.001 p<0.05 NS NS NS
Relationships NS NS NS NS NS
Performance p<0.05 p<0.05 NS NS NS
Qualitator
Physical Symptoms NS NS NS NS NS
Emotional NS NS NS NS NS
Relationships p<0.05 p<0.05 p<0.05 NS NS
Performance p<0.05 p<0.05 p<0.05 p<0.05 p<0.05
Table 3.4: Levels of significance, of the difference in scores, between
responders and non-responders at each point in the King's study, in separate
domains of the NHP and LASA and Qualitator
3.6 Discussion
There is no common currency of QoL measurement. In advanced breast
cancer, QoL comprises many facets and as in other cancers, symptoms change
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in importance between patients and over time (Clement Jones, 1985);
chemotherapy adds to this complexity. The recently developed Rotterdam
Symptom Checklist is a multidimensional instrument specifically designed for
advanced cancer patients on chemotherapy which measures many facets but at
intermittent timepoints (de Haes et al., 1990). The development of the
Qualitator represents a different response to the same perceived problem,
rather than an attempt to "reinvent the wheel" (Aaronson, 1988).
The frequency of diary completion allows few items. Geddes et al. used
a diary comprising eight obligatory items to measure QoL in lung cancer
patients receiving chemotherapy (Geddes et al., 1990). Fallowfield pointed out
that most QoL questionnaires have fixed components that might not be relevant
to an individual (Fallowfield, 1990). The Qualitator only measures five items on
any three week cycle. However, permitting the patient to define areas of her
life contributing most to its overall quality was the most novel and important
departure from more traditional instruments. Lumping symptoms altogether in
a global measurement is regarded by some as unscientific, akin to "trying to
compare apples and oranges". This, however, was the intention: the sum of the
parts was of overall interest. The number of changes of item made by patients
in both studies supports this view.
In spite of small numbers in both the King's and Guy's studies, the
Qualitator can predict patients likely to respond, supporting the findings of
Baum et al. (1980) and Ebbs et al. (1988a). Moreover, patients with high initial
scores had poorer survival, supporting the findings of Morris and Sherwood (1987)
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and Addington-Hall et al. (1990). The qualitator score was the most potent
indicator of prognosis of any of the factors recorded at the start of the King's
trial.
Compliance for diary completion overall was good in both the King's
study and Guy's study, comparing favourably with Geddes et al. who obtained
85%. In both studies, more weeks of diary completion were omitted by patients
on intermittent regimens who ran out of diaries during the treatment delay due
to neutropenic episodes. Aaronson advocates that QoL measures should be
capable of disaggregation (Aaronson, 1988). This can be done with the
Qualitator but, as with other instruments, subscales may not necessarily reflect
the paramount concerns of the patient. In any case it may be more appropriate
to apply a specific instrument to a specific area of interest (Ware, 1987). In the
original processing of the Qualitator data, it was found that analysis of
individual symptoms or domains can result in error. Following the method used
by Geddes et al. (1990), the only other group to have published details about how
they processed their data, the number of days all patients in one treatment
group spent with significant severity for a particular symptom were compared
using a chi-squared test. In the present study, it was possible to obtain a
statistically significant difference between Epirubicin and CMF for every
symptom, in one direction or other. After further scrutiny of this method, it
was realised that each individual patient's baseline level was not taken into
account, and that patients present in the study for differing durations were
exerting disproportional influence on the direction of the result. In all trials
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where QoL is measured, the QoL of patients who have left the study may
continue to be affected by the treatment they received, irrespective of
response. By measuring QoL only in patients still receiving treatment, a bias
is incurred which will tend to exclude non-responding patients, who have a
poorer QoL. This function of study design rather than instrument design may
favour the use of an intermittent QoL measure beyond the intended treatment
period.
The Qualitator is not presented as the long-awaited gold-standard and
modification may be desirable with experience. However, it does offer a simple
alternative to relying on clinical judgement alone. Collecting symptoms
together and measuring an overall score is feasible. It provides an alternative
or an adjunct to multi-dimensional measures with the aim of encouraging more
clinicians to incorporate QoL measurement into trial design.
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CHAPTER FOUR
Psychological screening for non specific abdominal pain
4.1 Summary
To determine whether Non Specific Abdominal Pain (NSAP) has a
detectable psychological contributor which could be used to predict outcome,
131 patients aged 14-40 admitted with acute abdominal pain were assessed using
the General Health Questionnaire and Hospital Anxiety and Depression
questionnaires, and a structured interview. In 61 patients with NSAP, more had
o
a psychosocial problem identified by the admitting registrar (x =7.28,ldf,p<0.01)
and marginally more had high questionnaire scores. The risk of having NSAP
was high if an abnormality on interview accompanied high questionnaire scores
(Relative Risk 1.93, 95%c.i. 1.35-2.77) or if prodromal pain had lasted more than
7 days (relative Risk 2.13: 1.55-2.92). After 2 years, patients with continuing
O
pain had higher HAD (x =6.57,ldf,p<0.02) and Spielberger anxiety trait
(x =6.50,ldf,p<0.02) scores; NSAP was associated with persisting pain (Relative
Risk 2.22, 1.10-4.48). Psychosocial factors are implicated in NSAP and in
chronic pain, but the sensitivity and specificity of questionnaire assessment are
too low to be useful in diagnosing NSAP. What promotes NSAP still remains




Previous studies of patients admitted with acute abdominal pain have
shown that 25-45% will remain undiagnosed, representing a large and unwelcome
burden on surgical resources. The term non-specific abdominal pain (NSAP) is
applied to this group but no common pathology has been demonstrated. In their
review of the subject, Gray and Collin concluded that a variety of possible
causes may include a psychological component in patients with otherwise benign
self-limiting conditions (Gray and Collin, 1987). No common psychological
pathology has ever been identified and in the only prospective study to date, in
which questionnaires were the only assessment tool, the findings were negative
(Raheja et al., 1990). A prospective study with long term follow up was
therefore undertaken in order to determine whether psychosocial factors were
implicated in patients with NSAP and whether, by screening with surgical
examination, structured psychological interview or questionnaires, outcome
could be predicted and admissions policy modified.
4.3 Objectives
1 To assess the likelihood of a psychological component to NSAP
2 To compare clinical methods with questionnaires in screening for NSAP
on admission
3 To assess the ability of questionnaires to identify patients whose
problems will not resolve following admission to hospital
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4.4 Patients and Methods
4.4.1 Patients
131 consecutive patients between the ages 14-40 were admitted with
abdominal pain to one surgical firm between October 1987 and December 1988.
They were asked to complete two psychological questionnaires, the Hospital
Anxiety and Depression Scale (HAD)(Zigmond and Snaith, 1983)(see Appendix 7)
and the 30 item General Health Questionnaire (GHQHGoldberg, 1972)(see
Appendix 8) . These are global psychological measures designed to detect
people at high risk of having psychiatric illness. After completion, the forms
were filed unseen. In a structured interview enquiring about recent marital
problems, life events or other emotional problems, the admitting surgical
registrar recorded the duration of symptoms, preliminary diagnosis and whether
an underlying psychosocial problem was suspected (see appendix 9). The process
of surgical management continued as normal and the discharge diagnosis was
recorded. The questionnaires were readministered to 63 patients who attended
the outpatient clinic at a median of 2 months. The hospital records of all
patients were examined after 1 year for details of histology, clinical course and
reattendance. A final diagnosis of NSAP was accepted if subsequent outpatient
attendance or investigation had resulted in a discharge from clinic without a
specific diagnosis. At a median of 2 years all 131 patients were contacted by
post to complete further identical questionnaires and another ad hoc
questionnaire to establish whether patients continued to have pain, whether pain
had been adequately dealt with at the time of admission, and whether further
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medical attention had been required. Patients were also offered a further
appointment (see Appendix 10). The Spielberger Anxiety Trait questionnaire was
introduced at this point (Spielberger et al., 1983)(see Appendix 11). Sixty eight
(52%) replied.
4.4.2 Scoring of questionnaires
After first follow-up, each admission questionnaire was scored. A high
score was defined by a total score above 10 for either the anxiety or depression
component of the HAD and above 5 for the GHQ (Zigmond and Snaith, 1983;
Goldberg, 1972). The Spielberger Anxiety Trait questionnaire scores at 2 years
were compared using a threshold of above 44.5, the mean score found in those
with psychiatric complications amongst general medical and surgical patients
(Spielberger et al., 1983). For all questionnaires and for the registrar's
assessment, the numbers of high and low scorers between the groups with
specific abdominal pain (SAP) and NSAP were compared at each stage using the
Chi-squared test. The scores of 63 patients who completed follow-up
questionnaires in the outpatient clinic and 68 who completed postal
questionnaires were compared with their respective admission scores using
Wilcoxon's signed rank test. The patients who responded to the question at two
years concerning continued abdominal pain were then considered separately:
questionnaire scores at each stage were compared between those with and those
without abdominal pain using the Mann-Whitney-U test and scores were




Patients were excluded from analysis only for the specific question or
questionnaire on which data were missing. On admission, all patients completed
the HAD correctly, but 8 (2 NSAP) failed to complete the second page of the
GHQ. For 9 patients, the record of the admitting registrar's psychosocial
assessment and for 14 the admission diagnosis were incomplete. At 2 months
the GHQ and HAD were incomplete for 4 and one respectively of the total of
63 patients. At 2 years, 2 NSAP and 2 SAP patients failed to answer the
questions about further pain.
4.5.2 Diagnoses
Sixty one (47%) had a final diagnosis of NSAP and 70 (53%) of SAP. The
final diagnoses and the sex distribution are listed in Table 4.1. The NSAP group
included five whose diagnosis was unconfirmed beyond hospital discharge. A
diagnosis of NSAP was made in 44% of males and 48% of females. There were
36 operations: of 33 appendicectomies, histology confirmed the diagnosis of
appendicitis in 24 patients. Normal appendices were removed from three
patients with no demonstrable pathology, one each with a diagnosis of Meckel's
diverticulum, pelvic inflammatory disease, enteritis, ruptured fimbrial cyst, and
cholecystitis. One patient had a pinworm infection and in the absence of acute
inflammation was classified in the NSAP group. Two patients with the diagnosis








NSAP 61 22(44) 39(48)
Appendicitis 24 13(26) 11(14)
Pancreatitis 5 1(2) 4(5)
Gynaecological 8 0 8(10)
Upper GI 16 8(16) 8(10)
Renal colic/UTI 10 3(6) 7(9)
Miscellaneous 7 3(6) 4(5)




Table 4.1: Number and percentage of each sex in each diagnostic group and
those undergoing unnecessary appendicectomy
4.5.3 Scores on admission and at follow-up
The percentage of patients with NSAP and with SAP having a high score
or a psychosocial problem at each stage are represented in figure 4.1. After the
interview, 38 were thought to have a psychosocial problem: 24 (44%) out of 55
with an eventual final diagnosis of NSAP and 14 (21%) out of 67 with SAP
(X2=7.28,ldf,p<0.01).
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Figure 4.1: Percentage of "cases" in each group according to each test used.
The two blocks in the right end of each bar indicate the extent to which the
number of cases in one diagnostic group exceeds that in the other.
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Although there appear to be more high scores in those with NSAP for the
HAD (anxiety) and the GHQ on admission, this was not statistically significant.
At 2 months and at 2 years the scores were even. This trend was observed in
the Mann-Whitney-U tests. Again this was not statistically significant (see
Table 4.2). Comparison of the admission score with the follow-up score of each
patient usingWilcoxon's paired rank test demonstrate no statistically significant
change for individual patients in either the SAP or the NSAP groups at 2 months
or 2 years (see Table 4.3).
NSAP SAP P
Admission HAD Anxiety 6 (n=61) 7 (n=70) 0.663
HAD Depression 3 (n=61) 3 (n=70) 0.241
GHQ 5 (n=59) 3 (n=64) 0.814
2 Months HAD Anxiety 5 (n=30) 5.5 (n=32) 0.740
HAD Depression 2 (n=30) 1 (n=32) 0.611
GHQ 3 (n=26) 1.5 (n=32) 0.392
2 Years HAD Anxiety 7 (n=26) 6 (n=42) 0.495
HAD Depression 2 (n=26) 2.5 (n=42) 1
GHQ 2 (n=26) 1 (n=42) 0.507
Spielberger 36.5 (n=26) 38 (n=42) 0.925
Table 4.2: Median questionnaire scores of SAP and NSAP patients at each
juncture
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NSAP P SAP P
2 Months HAD Anxiety 0.5 (n=30) 0.443 o D" II CO to 0.742
HAD Depression 0 (n=30) 0.867 0.5 (n=32) 0.276
GHQ 1.5 (n=29) 0.158 1 (n=32) 0.061
2 Years HAD Anxiety -0.5 (n=26) 0.332 0 (n=42) 0.868
HAD Depression -0.5 (n=26) 0.313 0 (n=42) 0.694
GHQ 0 (n=26) 0.888 0.5 (n=40) 0.539
Table 4.3: The median fall in paired questionnaire scores at each stage
(statistical comparison using Mann-Whitney test)
Few patients had high scores in the depression component of the HAD at
any stage. Of the nine patients who had a non-inflamed appendix removed,
including the four with NSAP, eight had normal questionnaire scores on
admission. The numbers of high questionnaire scores were similar amongst
males and females: 24% and 20% respectively for the HAD, 45% and 39%
respectively for the GHQ. Against this trend, a psychosocial problem was
diagnosed in 24% of males and 34% of females but this was not statistically
significant.
4.5.4 Assessment of admission data as screening tools
The relative risks and predictive values for a diagnosis of NSAP were
calculated for the variables recorded on admission and are shown in Table 4.4.
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HAD GHQ Psycho¬ Initial Pain HAD+ HAD
social Diagnosis >7 GHQ + GHQ
Problem NSAP days + Psych.
problem
Sensit¬ 26 49 44 47 15 24 21
ivity %
Specif¬ 81 67 79 86 99 86 97
icity %
Relative 1.25 1.41 1.71 2.24 2.13 1.35 1.93
Risk 0.84- 0.98- 1.18-2.48 1.57-3.21 1.55- 0.92- 1.35-2.77
(95% ci) 1.85 2.03 2.92 2.00




Table 4.4: Recordings on admission as screening tools for NSAP
In the 117 patients with a recorded admission diagnosis, the initial
diagnosis of NSAP was the single factor most strongly associated with a
subsequent final diagnosis of NSAP. The registrar's diagnosis of a psychosocial
problem was also significantly associated with a final diagnosis of NSAP; a high
score in the HAD and GHQ questionnaires, alone or combined, was not. An
admission diagnosis of NSAP was not associated with the diagnosis of a
psychosocial problem: (odds ratio 1.39, 95% c.i. 0.62-3.14) and there was no
significant association between the registrar's diagnosis of a psychosocial
problem and with the HAD or GHQ scores: odds ratios 2.31 (0.95-5.64) for the
94
HAD, 1.82 (0.82-4.05) for the GHQ.
Of 11 patients with high scores in both questionnaires and deemed to
have a psychosocial problem on interview, 9 had NSAP (Relative Risk 1.93: 1.35-
2.77). Of 9 patients with symptoms for more than one week before admission,
8 had NSAP (Relative Risk 2.13, 1.55-2.92).
4.5.5 Assessment of outcome at 2 years
In the 2 year postal questionnaire, four questions were asked (see
appendix 10). The replies to these questions are shown in Table 4.5.
n=64 NSAP, n=24
1) Still suffer from pain YES 21 (33%) 12 (x2=5.15, p<0.05)
2) Pain adequately dealt with YES 45 (70%) 16
3) Further medical attention YES 21 (33%) 10
4) Another appointment sought YES 4 (6%) 2
Table 4.5: The answers to questions asked in 2 year questionnaire
In answer to the first question, about continuing pain, more with an
o
anxiety trait were found among those who replied "yes" (x =6.50,ldf,p<0.02);
more had a high HAD at 2 years (x =6.57,ldf,p<0.02). Those with continuing
pain included more originally diagnosed as having a psychosocial problem
(x2=10.94,ldf,p<0.001) and more with a final diagnosis of NSAP
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o
(x =5.15,ldf,p<0.05). More patients with continuing pain also thought their pain
p
had not been adequately dealt with on admission (x = 4.82, p<0.05) and more had
p
sought further medical attention in the interim (x =5.43, p<0.02). There were
no significant differences in questionnaire scores according to responses to the
other questions. In Table 4.6, the risk of having continuing pain is compared for
each of the variables recorded on admission and at 2 years. The corresponding
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57% 24% 52% 53% 43% 43% 52%
Table 4.6: Factors associated with continuing pain at 2 years
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Pain No Pain P
Admission HAD Anxiety 8 (n=21) 5.5 (n=42) 0.213
HAD Depression 3 (n=21) 2 (n=42) 0.789
GHQ 7 (n=21) 2 (n=42) 0.239
2 Months HAD Anxiety 6 (n=10) 5 (n=25) 0.442
HAD Depression 3 (n=10) 2 (n=25) 0.163
GHQ 5 (n=10) 1 (n=25) 0.001
2 Years HAD Anxiety CM>100 5 (n=43) 0.008
HAD Depression 4 (n=21) 1 (n=43) 0.009
GHQ 3 (n=21) 1 (n=43) 0.127
Spielberger 46 (n=21) 35.5 (n=43) 0.046
Table 4.7: Median scores for patients with and without abdominal pain at 2
years
Pain P No Pain P
2 Months HAD Anxiety 0.5 (n=l1) 0.878 0 (n=25) 0.948
HAD Depression -0.5 (n=l1) 0.732 0.5 (n=25) 0.36
GHQ -3 (n=11) 0.114 1.5 (n=25) 0.07
2 Years HAD Anxiety -1 (n=21) 0.365 0 (n=43) 0.844
HAD Depression -2 (n=21) 0.078 0.5 (n=43) 0.137
GHQ 0.5 (n=21) 1 0 (n=43) 0.746
Table 4.8: The median fall in questionnaire score at each stage for patients
with and without abdominal pain
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4.6 Discussion
Many organic causes of NSAP have been suggested (Gray and Collin,
1987). NSAP is a loose concept binding disparate conditions but a significant
consumer of surgical resources. In this study, 47% of patients had NSAP. In a
study of 1190 patients with acute abdominal pain, 50.8% of patients aged 10-29
had NSAP (Irvin, 1989) and in a multi-centre study of 6097 patients the rate was
43% (De Dombal, 1979a). Because psychosocial aspects are seldom addressed
routinely, a genuine psychological or social problem may be overlooked. Authors
of previous studies assessing patients after operation or diagnosis have reported
that patients who had normal appendices removed were emotionally distressed
(Blanton and Kirk, 1947; Barraclough, 1967) or had an increased incidence of
adverse life events (Creed, 1981) but in the only prospective study low scores
were reported in NSAP patients and controls alike (Raheja et al., 1990). In
another study, of 105 patients, most of the 18 with NSAP were female and
scored higher in anxiety state-trait and illness behaviour questionnaires (Joyce
et al., 1986). In this study, NSAP and higher psychological scores were no more
common in women. Most of the patients undergoing unnecessary
appendicectomy had other surgical or gynaecological pathology and had if
anything, lower psychological scores. However, abdominal pain has been
claimed to be ameliorating in depression (Gomez and Dally, 1977).
A preliminary diagnosis of NSAP was the best predictor of a final
diagnosis of NSAP. The registrar's diagnosis of a psychosocial problem was
better than the HAD and GHQ but may have been encouraged where a surgical
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diagnosis was uncertain. However the preliminary diagnosis of NSAP and the
diagnosis of a psychosocial problem were not significantly associated. Some
feature, perhaps social rather than psychological, and independent of clinical
findings, was being detected less accurately by the HAD and GHQ, which could
not distinguish the anxiety surrounding acute hospital admission in patients with
SAP. A larger study may have established a significant difference. Even using
a positive score in both GHQ and HAD, 10 patients out of 25 would have been
wrongly diagnosed as NSAP, including three with appendicitis and two with
pancreatitis. The combination of psychosocial assessment, HAD and GHQ
identified a small but specific group at high risk of having NSAP, but similar
specificity was obtained simply by using a cut-off of more than seven days of
prodromal pain. In a study of 158 patients, the simple measure of recording a
"closed eyes sign" on abdominal palpation had a predictive value of 79% for
NSAP (Gray et al., 1988). De Dombal reported that computer assisted diagnosis
could reduce unnecessary admissions by 25% (De Dombal, 1979b) but this has not
been widely adopted, a probable drawback of any approach needing extensive
data collation.
The ability of a test to diagnose a patient having NSAP was expressed by
the relative risk. However, a more pragmatic approach is to calculate the
positive predictive value, which expresses as a percentage the chance of a
positive test being accurate in predicting NSAP. This is of direct value, as for
screening purposes, the only patients we are interested in identifying are those
who have a high probability of NSAP, and therefore may not need to be
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admitted to hospital.
Higher HAD anxiety and Spielberger trait scores were found in patients
with persistent pain at 2 years, but volunteer bias cannot be discounted since
compliance was low despite assiduous pursuit by mail and telephone. The
registrar's psychosocial diagnosis was the closest predictor of persistent pain but
it remains debatable as to whether psychosocial factors or pain come first.
Similar uncertainty as to the direction of causality arose from a study of the
irritable bowel syndrome, in which patients with bowel dysfunction had higher
HAD scores than controls (Heaton et al., 1991). Other studies have made use
of the concept of abnormal illness behaviour to study how bowel symptoms are
acted upon (Drossman et al., 1988); a similar approach might reveal the way in
which a person in the community becomes a patient with NSAP.
Amongst the unmeasured influences on the patient population in this
study are the referral patterns, which may change as GP fundholding and
purchasing become established. At present, the momentum acquired by a
patient already in the reception area and the fear of a missed diagnosis increase
the pressure to admit a patient with a questionable surgical diagnosis. To
reduce non-surgical admissions may require study of the referral process and in
future may be driven by reduced bed availability.
An adverse psychosocial history with positive questionnaires can identify
a small group of patients at high risk of having NSAP. However, the patient
with NSAP still remains easier to admit than to diagnose.
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CHAPTER FIVE
Health status measurement after minor surgery: a prospective study
5.1 Summary
To establish whether minor operations cause a perceived and measurable
improvement in health and QoL, 57 patients having day-surgery on a Waiting
List Initiative were studied prospectively. The NHP, HAD and GHQ were
completed before surgery and after 6 months by 81% patients, when an ad-hoc
questionnaire dwelling on perceived outcome of surgery was also completed. An
operative success was reported by 78%, improved health by 64%, improved QoL
by 69% and improved work efficiency by 54%. Improvements in HAD anxiety
(p=0.023), depression (p=0.035), NHP pain (p=0.001) and global NHP (p=0.034)
were recorded. In the perceived outcome questionnaire, patients reporting a
successful operation had had better preoperative GHQ (p=0.029) and HAD
depression (p=0.031) scores than those whose operation was not a success. Those
reporting an improvement in health postoperatively had worse preoperative NHP
scores to start with (p=0.027) than those who had no improvement. Minor
surgery results in improvements in both perceived and in objectively measured
health and QoL. Both are valid outcome measures for minor surgery.
Preoperative scores may be related to subsequent perception of outcome.
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5.2 Introduction
Evidence has emerged that at least one health authority has considered
excluding minor operations for non-life threatening conditions from its health
care provisions, pleading financial stringency (Godlee, 1991). This may have
been encouraged by evidence from health utility measures, which are based on
hypothetical trade-offs and tend to award low priority to such operations
(Cochrane et al., 1991).
The measurement of health status per se has gained momentum in
branches of medicine mainly concerned with chronic diseases and cancer
(Maguire and Selby, 1989). But more recently the techniques have also been
used to advance the cause of new or expensive technologies such as liver
transplantation or coronary bypass grafting (Tarter et al., 1991; Caine et al.,
1991). Where the outcome of treatment is, or has been assumed to be, obvious,
surprising results can occur, such as the failure to demonstrate any superiority
of extracorporeal shock wave lithotripsy over more invasive percutaneous
therapy for renal calculi (Mays et al., 1990). Only in one study has QoL been
measured during minor surgery for non-life threatening conditions and this
reported no change (Hunt et al., 1984).
To find out what, if any, benefit accrues to patients having these
operations, a prospective study was undertaken in which QoL was measured
before and after surgery using a variety of well validated instruments, to allow
wider comparison of results. In addition, patients were asked to comment on
the results of operation.
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5.3 Objectives
1 To determine if, and which, conventional instruments can be used to
measure the outcome of minor surgery
2 To compare prospective use of QoL questionnaires with a simple
retrospective questionnaire
3 To determine whether minor surgery does actually improve quality of life
5.4 Patients and methods
Fifty seven patients underwent day surgery in March 1991 as a result of
a King's College Hospital waiting list initiative. Patients were asked to
complete three Health Status questionnaires before surgery. The Nottingham
Health Profile (NHP)(Hunt et al., 1985) was chosen as a well validated
multidimensional instrument to indicate patients' overall health status. The
Hospital Anxiety and Depression Scale (HAD)(Zigmond and Snaith, 1983) and the
30-Question General Health Questionnaire (GHQ)(Goldberg, 1972) were chosen
in order to indicate whether a psychological improvement could be measured in
patients generally judged to be fit by conventional standards. In addition
patients were asked to record duration of symptoms and time on waiting list.
Between 6 months and 10 months (median 7.5) after the operation, the NHP,
HAD and GHQ were sent out by post together with a short questionnaire devised
to assess the perceived outcome of surgery (see Appendix 12). This included the
dichotomous questions: "Has the operation been as successful as you had hoped?"
and "Do you wish you had been offered the operation much sooner?" together
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with seven questions on general postoperative Health, QoL and function scored
on a five point categorical scale ("much worse", "worse", "same", "better" and
"much better"). Two more postal sweeps were made to non-responders, the final
one accompanied by a telephone call. Each component of the HAD, anxiety and
depression, gives a range 0-21, the GHQ gives a global score of 0-30 and the
NHP components of Emotional reactions, Energy, Pain, Physical mobility, Sleep
and Social isolation give a range 0-100 or added, give a global score of 0-600.
In keeping with standard practice in health status measurement, all
comparisons were made using non-parametric statistical methods. Paired
preoperative and postoperative scores were compared using the Wilcoxon signed
rank test. HAD, GHQ and NHP scores were then classified according to the
patients' responses to the postoperative perceived outcome questions: on
operation success (Yes or No), and health, QoL and function ("much worse,




Patients had been awaiting surgery for a mean of 1.9 years (range 0-4.7).
The operations were for varicose veins 30 (53%), hernia 8 (14%), anal lesions 5
(9%), skin lesions 7 (12%), ingrowing toenail 3 (5%) and 4 (7%) others.
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5.5.2 Missing data
The overall compliance rates for questionnaire completion are shown in Table
5.1. The health and QoL items were completed by all patients who answered the
perceived outcome questionnaire but there was a small attrition rate for the
other items which individual patients may have considered inapplicable to their
situation.
Preoperatively Postoperatively
GHQ 50 (88) 43 (75)
HAD 53 (93) 44 (77)
NHP 55 (96) 45 (79)
Successful operation? - 41 (72)
Preferred sooner? - 40 (70)
Health - 46 (81)
QoL - 46 (81)
Work efficiency - 38 (67)
Social life - 45 (79)
Sex life - 42 (74)
Interests & Hobbies - 45 (79)
Holidays - 45 (79)
Total number of patients 57 46
Table 5.1: Number (%) of patients completing each questionnaire
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Of the 11 patients who did not return questionnaires despite three postal
sweeps, seven who were contacted by telephone expressed satisfaction with the
operation and agreed to return questionnaires but none was received. Four
patients were untraceable.
5.5.3 Outcome measured by paired HAD, GHQ and NHP scores
In patients who completed both sets of questionnaires, there was a
significant improvement in the scores for HAD anxiety (median improvement 1,
range -4 to 6, p=0.023), depression (median 1, -8 to 9, p=035), NHP pain (median
8.74, -11.2 to 85.2, p=0.001) and global NHP (median 13.73, -75.8 to 167,
p=0.034). The medians and ranges of these scores, standardised to a scale of 1-
10, are illustrated in Figure 5.1. The ranges of change in these scores are








Figure 5.1: Box plots indicating medians and ranges of preoperative (1) scores
and postoperative (2) scores; Anx = HAD anxiety, Dep = HAD Depression.
Scores have been arithmetically adjusted to be comparable on a scale of 0-10
For key to interpretation of box plots used in this thesis, please refer to
Appendix 6.
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Figure 5.2: Box plots indicating medians and ranges of the change in score
following operation. The data for each instrument are arithmetically adjusted
to be comparable on a simplified range of 0-10 (a plus value indicates an
improvement)
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To give an idea of how these scores compare with NHP scores in another
study, the mean scores before and after surgery in the NHP domains have been
represented in graphical form in Figure 5.3 and are juxtaposed with the scores
from a study of 100 patients in whom QoL was measured before and after
coronary bypass grafting in Figure 5.4 (Caine et al., 1991).
Mean score
50 -i
EmotIon Energy Paln MoblI Ity SIeep
Domains of NHP
Before Cn=54D |M| After C"=45^
Mean score
50
Emotion Energy Pa I n Mob I I Ity SIeep Socla I
Domains of NHP
Before lljlj 3 months Egfl 1 year
Figures 5.3 and 5.4: Bar graphs indicatingmean NHP scores in the minor surgery
patients compared to those in a study of patients undergoing coronary artery
surgery (Caine et al., 1991).
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5.5.4 Perceived outcome
The responses to the perceived outcome questionnaire are shown in Table
5.2. Thirty two of forty one (78%) patients said the operation had been as
successful as they had hoped and 9 said not; 38/40 (95%) wished they had had
their operation sooner and 2 did not. The mean time off work was 2.1 weeks.
Much
worse
Worse Same Better Much
Better
Total
Health 0 1 (2) 15 (33) 22 (48) 8 (17) 46
QoL 0 1 (2) 12 (26) 23 (50) 10 (22) 46
Work
efficiency
0 2 (5) 16 (42) 16 (42) 4 (11) 38
Social life 0 1 (2) 22 (49) 19 (42) 3 (7) 45
Sex life 0 1 (2) 29 (69) 9 (21) 3 (7) 42
Interests &
Hobbies
0 1 (2) 30 (67) 11 (24) 3 (7) 45
Holidays 0 1 (2) 23 (51) 18 (40) 3 (7) 45
Table 5.2: Responses (%) in each category in perceived outcome questionnaire
5.5.5 Change in paired HAD, GHQ and NHP scores according to perceived
outcome
The responses to the perceived outcome questionnaire were used to
distinguish between two groups of patients for each item: those who reported
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an operative success, or not; an improvement QoL, or not; and similarly for
health, work efficiency, social life, sex life, hobbies and interests, and holidays.
The change in HAD, GHQ and NHP scores was then compared between the two
groups for each item. There was a tendency, in patients who perceived no
improvement, for HAD, GHQ and NHP scores to show a lesser improvement.
The median change in score was similar for each item between patients who
perceived a success, or improvement, and those who did not. Nevertheless,
ranking the changes in score demonstrated a significantly greater improvement
in NHP energy scale for those who perceived an improvement in health (p=0.018)
or QoL (p=0.026) and those who did not. The global NHP also showed a greater
improvement in those who perceived an improvement in health (p=0.043). There
was no statistical difference in other NHP scales, nor between patients who
perceived an improvement in the other items and those who did not.
5.5.6 Preoperative indicators of perceived outcome
When preoperative NHP, HAD and GHQ scores were compared, patients
who perceived the operation a success turned out to have had better scores than
those whose operation was not a success, in the HAD depression (medians 5
versus 2, p=0.031) and GHQ (medians 6.5 versus 1, p=0.029). Moreover, those
who perceived improved health as a result of surgery had recorded significantly
poorer global NHP scores preoperatively than those whose health was no better
after surgery (medians 64.9 versus 17, p=0.027). Patients who perceived an
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improvement in work efficiency as a result of surgery had recorded significantly
poorer global NHP scores preoperatively (75.8 versus 24.1, p=0.02). There was
no difference for the other items.
5.6 Discussion
Themajority of patients report an improvement in general health, quality
of life and function following minor surgery. This is supported by small, but
significant, improvements in psychological, pain and global health questionnaire
scores. These scores are proportionately better in patients who do report
improvements resulting from surgery, indicating that established general QoL
instruments may be used to measure outcome of minor surgery. As might be
expected, the improvements in QoL are proportionately less than those to be
obtained by coronary artery bypass grafting (Caine et al., 1991). The vast
majority wished that their operations had been done sooner and a majority
perceived an improvement in function.
Patients who reported an improvement in health and work efficiency had
poorer preoperative NHP global health scores, indicating that these patients had
genuinely impaired health-related QoL which was then improved by surgery.
Moreover, patients who considered their operation not to be a success had had
poorer preoperative depression scores and GHQ scores, suggesting an underlying
psychological modifier to their perception of outcome. An alternative approach
to the study design may have been to focus more precisely in the postoperative
perceived outcome questionnaire on the symptoms associated with each
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particular condition. However, as the conditions were heterogenous, the data
thus derived may not have been easily interpreted and the NHP proved a
suitable outcome measure for these conditions.
Ideally, this study should have had a control group which would go
through the same preoperative work-up and QoL measurement as the study
population, but not undergo surgery. However, there are reasons why this
approach was not adopted. The optimum control group would be treated
identically, except to be denied treatment. This is ethically unacceptable. An
alternative would be to measure QoL on patients in whom conservative
management or deferred surgery had been decided upon, but this group
represents a different patient population. This was the approach used by Hunt
et al. in patients undergoing minor surgery. They found no improvement nor any
difference in QoL between this and a control group, but conceded that the
control group could not be assumed to be closely matched (Hunt et al., 1984).
A compromise may have been to measure QoL of all patients on the
waiting list, and then to measure controls who remained on the waiting list. The
logistic problem that made this difficult was that on the waiting list initiative,
the objective had been to operate on all patients waiting more than a few
months. Another approach would be to compare a population of patients having
a different procedure, for instance liver transplant. The problem with this
approach is that again, this would represent a different patient population.
Compliance in the postoperative questionnaires was good and although volunteer
bias cannot be discounted, the direction which such bias might take is not
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readily surmised.
Conventional QoL measures and a simple unvalidated questionnaire can
be used to assess outcome in minor surgical procedures. Both demonstrate that
minor operations improve quality of life, but with the caveat that there was no
control population to compare with. To defer indefinitely such operations or
exclude them from NHS waiting lists is to deny measurable health gain to these
patients. This supports the inclusion of such operations in NHS provision.
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CHAPTER SIX
Discussion: The application of health status measurement to surgical practice
"As all scientific knowledge is only an approximation to the truth, with
sufficiently rigorous experimentation, the hypothesis will in time be falsified.
As an inevitable consequence of this act of falsification, new data will be
derived that will have to be incorporated as a new set of observations into a
new hypothesis that better fits all the data. This, in turn, will have to be
subjected to the most rigorous tests until it is once again found wanting. A
cascade of hypotheses, together with their refutations, develops, so that we
constantly approximate closer and closer to the truth, without ever having the
arrogance to believe that we have arrived at the ultimate goal." (Baum, 1989b).
The hypothesis is: Health status measures, scientifically applied, provide
important additional information to the surgeon.
In considering the hypothesis, it is first necessary to review what
additional information has been provided by the measurement of QoL in the
studies described. It is necessary to review the methodology employed, and the
potential drawbacks and finally, the recent literature concerning QoL
measurement in relation to surgical practice. The role and relevance of such
methods in surgical practice is discussed.
6.1 Additional information provided by QoL measurement
6.1.1 Comparison of treatment interventions
The chemotherapy study established, using conventional measures of
outcome, the UICC response criteria, that the aggressive chemotherapy regimen
was the more successful. It was anticipated that QoL measurement may
challenge this finding, but the results of the study confirm the findings of other
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studies that response per se is associated with improved QoL. In common with
other studies, the design of the chemotherapy study did not allow firm
conclusions to be drawn as to how each regimen affected the QoL of patients
not enjoying a response. They left the study on progression of disease. This,
together with the finding that nonresponders started off with a poorer QoL may
suggest chemotherapy had little opportunity to affect an already poor QoL, but
supportive care, such as pain control and hospice care could have been more
appropriate at this stage in their disease. The principle of QoL measurement
in this context is, however, vindicated. The use of frequent QoL measurement
and the innovation of a diary can be translated into other areas where, for
specific surgical interventions, a survival difference is not anticipated and
alternative interventions can only be assessed in terms of ongoing QoL. An
example might be pouch versus ileostomy following total colectomy, where
isolated postoperative QoL measurement may not give a complete account of
QoL changes over time.
A potential advantage of using a universal QoL instrument, the NHP, in
the minor surgery study was that direct comparison was possible with, for
example, the results of the study by Caine et al. on coronary artery bypass
surgery (Caine et al., 1991). Although purists rightly caution against comparison
between unlike populations, it may be helpful for surgeons to compare treatment
interventions between studies using a "gold standard", especially in the context
of the "quick, dirty experiment".
116
6.1.2 Measuring the health of populations- predicting outcome
Information regarding the anticipated outcome of treatment has a long
tradition in the surgical literature, and usually concerns survival and operative
morbidity. This depends upon the careful documentation of clinical signs and
clinical and laboratory staging of disease. However, such detail can be largely
absent from surgical practice outside specific studies, although computerised
audit may change this. A most significant finding from each of these studies
is that QoL scores prior to treatment could predict outcome.
The Qualitator score predicted response and survival in advanced breast
cancer patients undergoing chemotherapy in both the King's and the Guy's
studies. In the King's study, the LASA score was able to predict survival, the
NHP score to predict response and the qualitator to predict both. No single
factor pre-treatment predicted survival more accurately. The common-sense
view is that people in their terminal months know they are unwell because they
are weak, anorexic, in pain, or depressed and that these factors inter-relate.
That the QoL measurements appear to support this confirms their validity. If
this study is considered in isolation, it could be argued, however, that a large
amount of work has been done, in order merely to establish that QoL
measurement is as good a prognostic indicator as a simple liver scan. However
peripheral this finding may seem at present, it may be of singular value in
future, when difficult decisions are forced by renewed stringency in NHS
budgets. The finding that better response, and therefore better QoL were
obtained with the combination regimen (CMF) will comfort clinicians convinced
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of the benefits of aggressive chemotherapy. However, the finding that response
rates are predictable using QoL measurement offers the opportunity for a
deeper study into a gearing treatment strategies to individual patients.
In the NSAP study, health related QoL measurements alone were used to
try to identify the population at risk of having NSAP. However, the instruments
used were inferior to clinical judgement in predicting NSAP. The simple
expedient of recording the number of days' prodromal pain was better than
questionnaires at predicting which patients would have NSAP and on the
strength of this, QoL measurement would appear to have little to offer.
However, in the self-selected subgroup who responded to postal questionnaires,
the association between continued perception of pain and significantly poorer
anxiety scores indicates that expectations of treatment outcome amongst
individual patients differ, and can be measured numerically, and this may offer
guidance as to a worthwhile direction for future study. A measure more
appropriate to QoL and general rather than psychiatric health could perhaps
have increased the accuracy of the QoL data. Nevertheless, the patients in this
study with a degree of chronicity to their pain had consistently high scores at
all stages, suggesting that for some patients, their perception of physical health
may be less susceptible to physical intervention than might be supposed.
The small study of minor surgery patients demonstrated this phenomenon
quite clearly: patients claiming a poor outcome had significantly poorer
psychological scores before treatment. In this study, psychological and pain
scores were of use in predicting outcome, but weight was added to their results
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by the use of a general QoL instrument. Again, the common-sense view would
be that a practised clinician can tell which patients will benefit from treatment.
That this can be measured, however, may be of more than academic interest in
future.
There is a case, therefore, to be made for conducting more detailed
research upon predictors of outcome using QoL measurement in other areas to
see if such findings are replicated and to explore the potential applications.
6.1.3 Measuring the health of populations- measuring outcome
In the chemotherapy study, outcome was measured using established
methods and QoL measures. QoL measures supported the response data, but
predicted patients who would respond. In abdominal pain and in minor surgery,
outcome measurement is a poorly developed science. Mortality was zero in both
studies and wound infection rates (nil in the minor surgery patients and
inappropriate in NSAP patients) were irrelevant. The usual outcome measure
after surgical admission for non-life threatening conditions is the answer to the
question "How are you feeling now?" and in a busy outpatient clinic, this may
be of lesser interest than the presence of a healed wound or the absence of
surgical complications. It is possible that in each of these rather dissimilar
studies, QoL measurement would have given full and pertinent outcome data
even if uncomplemented by any other recordings. It is even possible to envisage
a time when the majority of routine surgical follow-up could be conducted by
postal questionnaire with the option of face to face encounter if desired.
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6.1.4 Making treatment decisions on individual patients
In each of the studies, it was demonstrated that an individual patient's
QoL measurement may be pertinent to their subsequent outcome, or perception
of outcome. However, the use of QoL measurement alone to decide on a
treatment strategy for an individual is frought with uncertainty. In the NSAP
study, QoL measurement was singularly unsuccessful in predicting which
patients would need surgical inpatient treatment, and in the other studies,
although QoL was a good indicator of groups, QoL was too nonspecific to be a
sole determinant of treatment in individuals. However, it could be envisaged
that, in the context of other information, QoL data may be of use. For
instance, in patients being assessed for routine interventions for non life-
threatening conditions, knowledge of an individual's psychological or pain score
may indicate the appropriate time scale for, or type of treatment. It is not
unreasonable, however, to expect that an attentive and sympathetic clinician
could evince such information without recourse to QoL measurement.
6.2 Methodological considerations
6.2.1 The choice of instrument
"Research into quality of life in medical care is dominated by sociologists
and epidemiologists. Due to the methodologists' lack of clinical practice, the
instruments available to them are far removed from clinical reality and are
inadequate or unacceptable for clinical purposes." (Troidl, 1991).
At the time of commencing the studies in this thesis, the instruments available
to measure QoL were either not specific for the conditions under study or
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deemed to be lacking in important respects. Independently, Ware and Aaronson
have suggested that in studies where QoL is measured, there should be a well
validated general questionnaire and that this should be augmented by a specific
questionnaire (validated, or ad hoc) focused on the condition being examined
(Ware, 1987; Aaronson, 1988). Both state that where a specific instrument
seems to be lacking for a particular angle of enquiry, existing instruments
should be adapted, rather than attempting to "reinvent the wheel". In the
studies comprising this thesis, this advice was followed.
In the chemotherapy study, the NHP and the LASA were chosen as the
best available validated instruments. As judged by their ability to support the
known facts on QoL in advanced cancer patients, this decision was correct. The
development of the Qualitator was to fulfil a perceived gap among the then
currently available instruments in capturing day-to-day variations in cancer
chemotherapy patients and so a degree of de novo development was necessary.
The finding that, using basic concepts which were not original, it was possible
to derive a reasonably competent measure of QoL would support the adaptation
of other instruments to surgical uses without repeating the whole development
process. For instance, changing a few of the items of the Qualitator may make
it an acceptable instrument for other conditions. Many possible applications
unfold.
In the abdominal pain study, no generic QoL measure was used and this
is a flaw because as a result, no data were available concerning any change in
general health status. Thus the psychological factors had to be studied in
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isolation, without any reference to, say, the pain experienced by these patients.
This was addressed in the issuing of the postal questionnaires at 2 years, with
interesting results concerning the perception of continuing pain- despite the
poor response.
In the minor surgery study, this omission was rectified, with the inclusion
of the NHP, which yielded important additional information regarding pain and
general health.
In the latter two studies, the simple ad-hoc questionnaires yielded
additional significant information. They were kept simple, and designed along
lines recommended by other authors (Fitzpatrick, 1990). They were, however,
unvalidated. Although several authors caution against using unvalidated
measures, citing as a particular problem their face and content validity, Troidl
points out the profound influence on peptic ulcer surgery which resulted from
the use of an early, unvalidated measure, the Visick scale (Troidl, 1987). On a
more practical level, all new measures are unvalidated when new. A more
subtle drawback is the suspicion with which untried measures may be treated by
other specialists.
A glance at the appendices to this thesis will confirm that QoL
instruments are relatively uncomplicated. Moreover, having noted the problems
associated with using an unvalidated instrument, for internal comparison in the
same study using randomised controls or baseline control scores, there is no
reason why such measures should not yield pertinent and useful information.
However, in order to allow a more general appreciation or comparison in the
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context of other studies, it is wise to use a validated measure as well. It is
necessary that if QoL measures are to be widely used by surgeons, their
simplicity be made known and some general instruments be adopted for
comparison between studies.
6.2.2 Frequency of testing
In the vast majority of studies where QoL is measured, measurement is
made once, before a treatment intervention and on a limited number of
occasions afterwards. Little specific advice exists in the literature as to how
often measurements should be made. Cox et al. (1992) advise of the need for
base-line observations, avoidance of unnecessary assessments to the detriment
of doctor or patient compliance and targeting of assessments a) to distinguish
early from late treatment effects, b) to reflect the pattern of treatment
administration and c) to concentrate measurements when maximum treatment
response is expected. In the studies described, this pattern was generally
followed, although it could be argued that more frequent measurement would
have elicited useful information about the status of the acute abdominal pain
patients during and immediately after their hospital stay, and similarly for the
minor surgery patients. However, the logistics prohibited this. The use of the
Qualitator, a diary, would seem to have been an appropriate solution to the
logistical problem in the chemotherapy patients, and may be a useful line of
investigation in the future in studies involving perioperative patients.
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6.2.3 Compliance
A methodological problem common to all the studies is the rate of non-
response to questionnaires. This is especially relevant to postal questionnaires
and to studies of patients who are basically physically well. Poor patient
compliance is blamed for deficiencies in design or conduct of many studies, not
just those involving QoL measurement. However, in QoL studies, it is
particularly important that the completion rate is good and this is the
responsibility of the clinician. The studies in this thesis suffer from a poor
completion rate in a variety of ways. The most notable is in the abdominal pain
study, in which the two year questionnaires were returned by only 52% of
patients- despite two postal sweeps and telephoning by a research assistant. In
the minor surgery study, in which follow-up was shorter, and in which three
postal sweeps were sent, together with telephoning of the intransigent non-
responders by the principle investigator, the fall-out rate was still 19%. In the
chemotherapy study, data were not gathered when the routine was upset by
treatment delay or progression of disease. In every study, at every stage,
therefore there was a loss of data, introducing the possibility of volunteer bias.
The effect of this on the validity of each study's findings is not known.
However, if it is accepted that even with committed investigators such gaps
could occur, it is logical that a less committed approach may produce larger
gaps. This is probably one of the major flaws in any QoL study, and one for
which there is no single solution; the general rule that it only takes one
committed person to make a success of such studies still applies, however. This
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view is emphasised by Williams in a discussion of QoL strategies in Surgery
(Williams, 1991). It does also affect the potential of QoL measurement as a
routine tool in surgical audit.
An ethical problem arises in the pursuit of non-responders. To do so too
assiduously may be to breach the ethical line which should prevent the
researcher from interfering with the QoL of the patient. Patients have, after
all, a right not to comply. This calls for tact, discretion and persuasiveness in
addition to empathy on the part of any investigator in the field of QoL research,
a factor often omitted in the discussion of methodological issues in QoL
research. In this respect, QoL research has much in common with the older
science of market research, already a valued tool in the manufacturer's
armamentarium, but subject to the vagaries of public opinion and individual
mood.
6.2.4 Statistical considerations
In spite of the amount of work done in recent years to validate
instruments which measure QoL, relatively little has been written on how to
process the data which accrue from QoL measurement. This has been discussed
previously (section 1.4). Although non-parametric tests are relatively easy to
perform, there arose several problems in the conduct of these studies which
have not been addressed in the literature and for which, moreover, three
statisticialns consulted by the author, and attendance at a forum on the very
subject (Cox et al., 1992), offered no clear answers.
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First, is the question of when do patient numbers in a study become large
enough to justify logarithmic transformation of the data? This issue was
avoided altogether because of the ample justification in the literature for using
non-parametric tests, but there may have been a considerable loss of sensitivity
as a result.
Second, is how to cope with missing data. This was handled in a variety
of ways in this thesis, but no help was gleaned from published literature, which
is presumably heavily biased in favour of studies with near-complete databases.
In the Qualitator studies, the odd day, week or even month of missing data was
simply given the mean score for the measurements on either side. Looked at
closely, this method is rather unscientific, as it cannot be assumed that quality
of life carried on in a continuum during the missing period. Anything could have
been happening- in fact, in those with marrow toxicity, QoL could have reached
a low. In the chemotherapy patients who had missing NHP or LASA data at any
point during the study, these were omitted from the analysis. However, the
effect of having these "holes" in the data, is to reduce the validity of the
overall analysis. The only solution which appeared honest was to perform a
separate comparison each month, with the pre-treatment scores, with the data
available, rather than to use a method requiring complete data, such as the
Friedman analysis.
The other problem is the fall-out rate of patients from the chemotherapy
study. This was tackled in two ways: again, by analysing data every month; then
by comparing responders in both groups (as it is the responders who generally
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remained in study the longest). Only one paper addressed this problem directly-
in response to a similar fall-out in animal tumour immunotherapy experiments
(Koziol et ah, 1981). This method, which involves calculation of a multivariate
rank statistic and its permutation distribution, would probably have been
entirely appropriate, but was not used in the end, because, on a pragmatic level,
the data analysis (intended to be repeatable by others) was already becoming
unduly complicated.
In the NSAP and minor surgery studies, the absence of data at entry, or
follow-up effectively removed the patient from that particular analysis,
reducing the power of the studies at each point of data collection. As
mentioned before, there is only one solution to this- better data collection at
the time. The alternative is to repeat all questions again at a later timepoint
and include this as a separate analysis.
Finally, threshold scores, which were used to denote "caseness" in the
NSAP study, but avoided in the minor surgery study, may distort the data. When
comparing two groups, and not necessarily wishing to quantify them for out-and-
out psychological pathology, is is better to use comparative non-parametric
tests. In fact, both methods were used in this study, and no differenc found in
the overall results. However, the raising or lowering of the threshold score in
the Spielberger data would have removed any statistical difference between the
"Pain" and "No pain" groups, when the Mann-Whitney confirmed that there was
such a difference (Table 4.7).
Amongst other impediments to the easy statistical processing of Qol
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data, the one most consistently encountered during the background reading for
this thesis was how, even in papers in reputable journals, so little space was
devoted to the details of statistical methods.
6.2.5 Allocating resources
One of the biggest obstacles to the introduction of new research methods
into clinical practice is the time which is required to gather the data. Very
often the data gathering is left to the most junior member of the medical or
nursing staff. If, as is usually the case, this person has little or no personal
investment in the project, then data collection will be deficient. In all the
studies described in this thesis, the vast majority of data were collected by the
author. Where this was not the case, co-investigators had considerable
commitment to the study in question. In the chemotherapy study, the time
involved in administration of treatment, counselling and QoL data collection
alone was two days per week for the 18 month duration of the study, followed
by several months of data processing. In the other two studies, administration
of the control questionnaires was conducted by a variety of staff, at a total cost
in time of about 20 minutes per patient. The postal questionnaires took
considerable time to organise. Finally, the processing of data from the latter
two studies took approximately two months. So the time consequences of
setting up a study in which QoL is to be measured properly are considerable and
should be planned for at the start. Ideally, one person should be responsible for
data collection. Where this is not the case, compliance inevitably deteriorates,
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threatening the validity of the eventual findings of the study.
6.3 The current state of QoL measurement in surgical practice
So what has been happening in surgery and how does the surgeon stand in
relation the QoL research that developed in the last two decades? In 1989,
Troidl suggested several areas in which QoL could be measured in Surgery (see
Table 6.1).
Clinical situation Surgical examples Ranked importance
of outcome
variables
Impaired QoL but not life
threatening
Impaired QoL and life
threatening: surgery prolongs





Trade-off between better QoL












































Table 6.1: Example of ranking the importance of outcome variables in surgical
conditions (Troidl, 1991)
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In 1987 it was reported that only 3% of trials reported in surgical journals
mentioned QoL (O'Young J and McPeek B, 1987). Four years later, there has
been progress. Studies measuring QoL have been reported in neurosurgery
(Schulte et al., 1987; Bach et al., 1988; Stewart-Amedei and Penckofer, 1988;
McKenna et al., 1989; Trojanowski et al., 1989), carotid endarterectomy (De
Leo et al., 1987), head and neck cancer (Strauss, 1989; Rathmell et al. 1991),
congenital heart disease (Shimada and Tsunemoto, 1990; Torii et al., 1990;
Aigueperse and Marechal, 1991), coronary artery and valve surgery (Mayou and
Bryant, 1987; Langeluddecke et al., 1989; Rogers et al., 1990; Jenkins et al.,
1990; Caine et al., 1991; Booth et al., 1991), cardiac dysrhythmia surgery (de
Carvalho et al., 1989), heart transplantation (Lawrence and Fricker, 1987; Mai
et al., 1990), aortic aneurysm (Rohrer et al., 1988), oesophageal and
gastrointestinal surgery (Habu et al., 1988; Sakamoto et al., 1989; Roder et al.,
1990; Buhl et al., 1990; Nogughi et al., 1991), hepatobiliary surgery (Spina et al.,
1988; Little and Wong, 1991), liver transplantation (Kober et al., 1990; Tarter
et al., 1991), colorectal surgery (Kennedy, 1988; Yasutomi et al., 1988;
Drossman et al., 1989; Oresland et al., 1989; Pemberton et al., 1989; Walsh et
al., 1990; Anseline, 1990), benign and malignant prostatic surgery (Fowler et al.,
1988; Singer et al., 1991), renal tract stones (Mays et al., 1990), gynaecological
cancer (Sichel, 1990) and early breast cancer (Ganz et al., 1990), However, in
1991, no study reported in the British Journal of Surgery contained QoL
measurement of any description, even though several would have uncovered
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clinically relevant information by doing so. Why should this be, especially when
the practice of audit has been deeply rooted in many surgical centres and is set
to become established in many more?
6.4 The Meran consensus conference
Many areas of contention in surgical practice come down to straight
Quality of Life issues. This was recognised by a group of surgeons and QoL
methodologists who met in Meran, Italy, in October 1989 to discuss the issues
and to formulate objectives and guidelines for QoL measurement in surgical
practice (Neugebauer et al., 1991a). It had been recognised that in a changing
world, traditional technical measures of surgical success were no longer
sufficient justification for surgical treatment. The conference met in small
multidisciplinary groups in the specialties of transplantation, thoracic,
cardiovascular, trauma/orthopaedic and abdominal surgery to select related
diseases where formal QoL assessment was a priority, to consider how useful
such information was in deciding whether to operate or not, and to monitor or
evaluate patient status. The important QoL domains in each disease state were
defined (see Table 6.2) and finally, the QoL instruments were reviewed. The
results were then presented by each group to a plenary session and are
summarised in an issue of Theoretical Surgery given over to the reporting of the
conference (Neugebauer et al., 1991b). Each specialty group provided a
comprehensive list of specific situations in which QoL measurement would be
appropriate.
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There was broad agreement as to the obstacles which prevent QoL
measurement being taken up widely at present. First was the perception
amongst clinicians used to handling laboratory or pathological data that QoL
measurement somehow represents "soft", or less respectable data. Second, was
the perception amongst surgeons that their clinical judgement of a given
situation was likely to be more reliable than QoL data derived from such a
situation. Third, was the complaint that QoL measurement would consume
significant resources from those whose workloads were already considerable.
More specifically, the sheer number of QoL instruments, without a definite "gold
standard", may act as a deterrent to their use and finally, evidence is still
lacking that, even in specialties where QoL research has been most prolific, the
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6.5 The future of health status measurement in surgical practice
Evidence is lacking, as to whether or not treatment or management
policies of people who do not conduct QoL research have been substantially
altered by the results of those who do. This is illustrated by the abandonment
of amputation in favour of limb-sparing surgery for extremity sarcoma despite
evidence that QoL was no better in patients having the conservative procedure
(Sugarbaker et al., 1982). This may in part be due to ignorance amongst
clinicians of work on QoL (Troidl, 1991). It is noteworthy that in plastic
surgery, a specialty where QoL must be the major, if not the only endpoint, in
no study in the decade up to 1990 was QoL measured as an endpoint (Spilker and
Stark, 1991).
In the reorganised NHS and with the advent of the Patients' Charter, and
competition for the internal market, QoL considerations may require more
complete documentation and may, in future, be scrutinised more closely than
was previously considered necessary. That the technology now exists, as
indicated by these studies, offers cold comfort to surgeons already steeling
themselves to deliver more accurate audit. However, if surgeons became
familiar with the potential advantages and pitfalls of QoL measurement, they
could rely less heavily upon the skills of the methodologists, who are less
familiar with the complexities of the delivery of surgical care. The
incorporation of QoL measurement into clinical audit is technically feasible, and
is one of the few ways in which treatment strategies can be evaluated other
than by measures of survival, complications and activity.
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6.5.1 The changing climate in health care delivery- non-surgical considerations
The two biggest influences on treatment strategy are still the amount of
available resources on one hand, and the interacting goals of provider and
consumer on the other. The latter factor is influenced largely by fashion, which
includes the provider-driven introduction of new technologies. If QoL research
is to have any bearing upon the practice of surgery, then neither in the
reorganised NHS nor in health systems similarly constrained financially, will it
still be a matter left to the discretion of the surgeon as in days of old. The
purchaser of surgical services is now all-powerful.
The danger is that QoL data may not be used to make impartial
judgements on scrupulously gathered and processed data, leading to changes in
treatment practices where appropriate, but to support dogma:
"It is a common failing- and one that I have myself suffered from- to fall in love
with a hypothesis and to be unwilling to take no for an answer. A love affair
with a pet hypothesis can waste years of precious time." (Medawar, 1979).
It therefore becomes all the more important that a scientific approach evolves
to the measurement of QoL and health status in surgical practice, with well
validated instruments and methodology.
From the three studies described, it can be seen that a large amount of
data accrue. Depending upon the views of the author, such data can be adapted
or omitted to suit the goals of the study. It is important, therefore, that a
study involving QoL measurement starts out with a clear a priori hypothesis
which is not adapted or forgotten under the deluge of data which accumulate.
This will become even more relevant as there is considerable commercial
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advantage to be gained by drug companies which can demonstrate a QoL
advantage to their particular product: many more pharmaceutical companies are
using QoL measurement in their trials (Luce et al., 1989). This early in the use
of QoL measurement in surgery, no consensus has yet formed as to the
approaches to be adopted.
6.5.2 Surgical trends
The delivery of health care in Europe and in the USA is becoming much
more carefully costed and, consistent with social trends, much more consumer-
sensitive. It is inevitable that the delivery of surgical services will bend to the
same influences. There is recognition amongst influential surgeons in the UK
not only that closer scrutiny of outcome is warranted, but that the structure and
process of the delivery of surgical services be examined (Bates, 1990;
Kettlewell, 1990; Ellis, 1991). The Royal college of Surgeons of England has an
Audit Unit, and although its main efforts are directed towards the
standardisation of information gathering regarding process and mortality,
amongst other projects underway is the Patient Satisfaction Study, designed to
assess the extent to which the clinical treatment and outcome meets the
patients' expectations of care and recovery (Emberton et al., 1991). This
involves validation of questionnaires which clinicians can use routinely to
investigate whether services meet patients' expectations and requirements and
it will examine closely the whole process of surgical care delivery, as it is
experienced by the patient (Meredith, 1991). Health status measurement has
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been sanctioned by the English Royal College of Surgeons in assessing the
outcome in prostatectomy patients (Emberton, 1992). A study in the Freeman
Hospital, Newcastle has now gathered a large number of patients in whom the
NHP has been used to measure outcome (Coles, 1990). This study has bridged
the period during which laparoscopic cholecystectomy has all but taken over as
the orthodox treatment for gallstones so the results will be of great clinical
relevance during the tidal wave towards the laparoscopic operations.
Baum has argued eloquently for the randomised trial, and quotes
Maimonides, of 12th century Alexandria: "Teach thy tongue to say I do not
know, and thou shall progress". David Hume, the Scottish philosopher averred:
"No testimony is sufficient to establish a miracle unless the testimony be of
such a kind that its falsehood would be even more miraculous than the fact
which it endeavours to establish" (Baum, 1989a).
The trouble is, that the basic instinct of surgeons and patients alike is to search
for and seize upon the miracle cure.
Minimally invasive surgery (MIS) is the most obvious example of a
"quantum leap" in contemporary surgical practice. This area seems to be well
suited to QoL research, as the main reason for performing MIS is to reduce the
incidence of wound pain and the length of hospital stay, so improving the quality
of life of the patient undergoing such surgery. Amongst the minimally invasive
operations, laparoscopic cholecystectomy does seem truly miraculous and has
now become the "norm", so that the opportunity to conduct a randomised trial
of this, with conventional cholecystectomy, measuring QoL, has almost certainly
been lost.
137
The rapid introduction of laparoscopic cholecystectomy has presented
enquiring surgeons with a dilemma. On one hand no clinician would wish to deny
their patient the option of a less invasive procedure; on the other, there is a
learning curve, and there is anecdotal evidence that considerable morbidity may
result from laparoscopic procedures. The "obviously" better treatment may not
be so much better after all, as was found by Mays et al. who reported no
difference in QoL between patients having extracorporeal shock wave lithotripsy
compared to the more invasive percutaneous therapy (Mays et al., 1990).
However, even if a measured strategy were acceptable to clinicians, then it
would probably not be acceptable to patients. Neugebauer et al. believe they
have done the next best thing, which is to measure as many outcome indicators
as they can, including QoL, as their laparoscopic cholecystectomy programme
accelerates (Neugebauer et al., 1991c). What will be the conclusions in five
years' time? The indications at present are that laparoscopic cholecystectomy
may have cost some patients a vastly impaired QoL or even their lives in order
to give the rest a marginally improved QoL. Under such circumstances,
measurement of QoL may have singular importance in establishing the correct
approach to gallbladder disease. The relative merits of conservative or
operative treatments would only have been quantifiable if, in addition to the
other measures of process and outcome, QoL measurement had also been
undertaken.
Although examples of important QoL issues in surgery are many, QoL
measurement will not suddenly transform surgical research and practice.
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Moreover, there is not an obvious single method of quantifying QoL for all
situations, however attractive the simplistic approach may seem: "The answer
to the question of the meaning of life is.. 42" (Adams, 1979). However,
momentum is gaining and certain key studies are likely to appear in the coming
years. They will command wider attention which may encourage others to
undertake further research (Goligher, 1987). The principles and practice of QoL
measurement in surgery will only become clearly delineated thereafter. From
the studies in this thesis, some pointers emerge: Reliable data can be obtained
by including a general, well validated measure, and a specific, simple measure
directed towards the condition under study. In trials, controls should, where
possible, be used. Statistical analysis should be by simple, nonparametric
methods. The pre-intervention QoL of study patients may have considerable
bearing upon the post-intervention QoL measurements. Common sense is one
of the most important ingredients in QoL research.
In the area of surgical audit, which as mentioned previously is becoming
standardised, it may be that if computer software should allow later inclusion
of outcome measurement using QoL, built in to the data capture systems, self-
assessment questionnaires could form a key part of the process of surgical
admission, discharge and follow up, and contribute much information, not just
about the achievement of treatment objectives, but about the whole "surgical
experience" seen from the patient's viewpoint- as yet uncharted territory.
Centuries after the dawning of the "Age of Enlightenment" there is still a
paucity of objective information on how surgery touches the lives of those
139
undergoing it.
The role of health status measurement in surgical practice is not yet
defined. Its measurement in specific studies seems set to increase, but such
studies will only gain credence if they are properly conducted. This will only
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APPENDIX 1
CRITERIA OF RESPONSE IN SOLID TUMOURS
(UICC/WHO)
Complete Response (CR)
Complete disappearance of all clinically detectable malignant disease. No new
lesions. Patients with bone metastases should have reversion to normal of all X-
rays
Partial Response (PR)
50% or greater decrease in tumour size, without increase in size of any area of
known malignant disease. No new lesions.
(i) Measurable bidimensional: 50% or greater decrease in tumour area
(multiplication of two greatest diameters) or 50% decrease in sum of
products of perpendicular diameters of multiple lesions.
(ii) Measurable unidimensional: 50% or greater decrease in linear tumour
measurement.
(iii) Non-measurable: Appreciable change confirmed by photography or
radiography, agreed upon independently and objectively.
No Change (NC)
No significant change in measurable lesions (<50% decrease or <25% increase in
size) and no new lesions.
Progressive Disease (PD)
Significant increase (>25%) in size of some or all lesions present at start of therapy
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APPENDIX 3 The Nottingham Health Profile
Below are some problems people may have in their daily life. Look down the list
and put a tick in the box under YES for any problem you have at the moment.
Tick the box under NO for any problem you do not have. Please answer every
question. If you are not sure whether to answer YES or NO, tick whatever answer
you think is more true at the moment.
YES NO
I'm tired all the time
I have pain at night
Things are getting me down
I have unbearable pain
I take tablets to help me to sleep
I've forgotten what it's like to enjoy myself
I'm feeling on edge
I find it painful to change position
I feel lonely
I can only walk about indoors
I find it hard to bend
Everything is an effort
I'm waking up in the early hours of the morning
I'm unable to walk at all
I'm finding it hard to make contact with people
The days seem to drag
I have trouble getting up and down stairs/steps
I find it hard to reach for things
Remember, if you are not sure whether to answer YES or NO to a problem, tick
whichever answer is more true at the moment
YES NO
I'm in pain when I walk
I lose my temper easily these days
I feel there is nobody I am close to
I lie awake for most of the night
I feel as if I'm losing control
I'm in pain when I'm standing
I find it hard to dress myself
I soon run out of energy
I find it hard to stand for long (eg at the kitchen sink, waiting
for a bus)
I'm in constant pain
It takes me a long time to get to sleep
I feel I am a burden to people
Worry is keeping me awake at night
I feel that life is not worth living
I sleep badly at night
I'm finding it hard to get on with people
I need help to walk about outside (eg a walking aid or someone
to support me)
I'm in pain when going up and down stairs/steps
I wake up feeling depressed
I'm in pain when I'm sitting
APPENDIX 4. LASA (Priestman and Baum)
Instruction Sheet
The doctors and nurses looking after you are concerned about your quality of life.
We would like you to tell us how you have been feeling recently.
The first time you fill in this form, someone will explain to you how to mark it. If you
need help, please ask the doctors or nurses.
There is a list of items that people with your disease undergoing treatment are often
concerned about.
One of the spaces (marked "Other") is left free for you to tell us about any item that


















































Able to do Housework
Impossible
Able to Perform Chores
Impossible








How would you rate
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APPENDIX 6
Key to interpretation of box plots (SYSTAT, Inc)
The box plot is a means of representing non-normally distributed data diagramatically.
The median of the batch is marked by the centre
horizontal line and splits the batch in two. The lower and
upper boundaries of the enclosed box (the "hinges") split
the remaining halves in half again.
Hspread is the term used to denote the interquartile range,
i.e. the absolute value of the difference between the
values of the two hinges.
The inner fences are defined as follows:
lower fence = lower hinge - (1.5Hspread)
upper fence = upper hinge + (1.5Hspread)
The outer fences are defined as follows:
lower fence = lower hinge - (3Hspread)
upper fence = upper hinge + (3Hspread)
The whiskers show the range of values which fall within
1.5 Hspreads of the hinges. They do not necessarily extend
to the inner fences.
Values outside the inner fences are plotted with asterisks.
Values outside the outer fences are plotted with empty
circles.
The adjacent hypothetical example represents the
difference in absolute values of total NHP score between
preoperative and postoperative measurements, for each































36.8, 58.56, 19.87, 30.67, 0, -75.81, -25.21, 1.61, 139.58,
21.04, -55.5, 36.57, 0, 0, -71.74, 167.04, 0, 3.75, 23.41,
169.51, -11.07, 0, 11.43, 0, -12.57, 212.75, 0, 116.26,
47.18, 49.67, 91.45, 12.91, 49.71, 24.13, 123.01, -43.47, 114.28,
-100
-82.98, 43.58, 9.76, 164.69,
-11.22, 31.65, 30.4, -69.63, 27.47, 11.2, 31.38, 104.1, 0, 30.67, 0, -23.55, -13.52, 12.91, 0, 1.51
APPENDIX 8
GENERAL HEALTH QUESTIONNAIRE
Please read this carefully:
We should like to know if you have had any medical complaints, and how your health has been
in general, over the past few weeks. Please answer ALL the questions on the following pages simply by
underlining the answer which you think most nearly applies to you. Remember that we want to know
about present and recent complaints, not those that you had in the past.
It is important that you try to answer ALL the questions.
Thank you very much for your cooperation.
HAVE YOU RECENTLY:
1 been able to concentrate on Better Same as Less than Much less
whatever you're doing? than usual usual usual than usual
2 lost much sleep over Not at all No more Rather more Much more
worry? than usual than usual than usual
3 been having restless, Not at all No more Rather more Much more
disturbed nights? than usual than usual than usual
4 been managing to keep More so Same as Rather less Much less
yourself busy and than usual usual than usual than usual
occupied?
5 been getting out of the More so Same as Less than Much less
house as much as usual? than usual usual usual than usual
6 been managing as well as Better About the Rather less Much less
most people would in your than most same well well
shoes?
7 felt on the whole you were Better About the Less well Much less
doing things well? than usual same than usual well
8 been satisfied with the More Abo u t Less satis¬ Much less
way you'vecarried out your satisfied same as fied than satisfied
task? usual usual
9 been able to feel warmth Better Abo u t Less well Much less
and affection for those than usual same as than usual well
near to you? usual
10 been finding it easy to get Better Abo u t Less well Much less
on with other people? than usual same as than usual well
usual
11 spent much time chatting More time Abo u t Less time Much less
with people? than usual same as than usual than usual
usual
12 felt that you are playing a More so Same as Less useful Much less
useful part in things? than usual usual than usual useful
13 felt capable of making More so Same as Less so than Much less
decisions about things? than usual usual usual capable
HAVE YOU RECENTLY:
14 felt constantly under Not at all No more Rather more Much more
strain? than usual than usual than usual
15 felt you couldn't overcome Not at all No more Rather more Much more
your difficulties? than usual than usual than usual
16 been finding life a struggle Not at all No more Rather more Much more
all the time? than usual than usual than usual
17 been able to enjoy your More so Same as Less so than Much less
normal day-to-day than usual usual usual than usual
activities?






19 been getting scared or Not at all No more Rather more Much more
panicky for no good than usual than usual than usual
reason?
20 been able to face up to More so Same as Less able Much less
your problems? than usual usual than usual able
21 found everything getting Not at all No more Rather more Much more
on top of you? than usual than usual than usual
22 been feeling unhappy and Not at all No more Rather more Much more
depressed? than usual than usual than usual
23 been losing confidence in Not at all No more Rather more Much more
yourself? than usual than usual than usual
24 been thinking of yourself Not at all No more Rather more Much more
as a worthless person? than usual than usual than usual
25 felt that life is entirele
hopeless?






26 been feeling hopeful about More so








27 been feeling reasonably More so About Less so than Much less
happy, all things than usual same as usual than usual
considered? usual
28 been feeling nervous and
strung-up all the time?






29 felt that life isn't worth
living?
Not at all No more Rather more Much more
than usual than usual than usual
30 found at times you couldn't
do anything because your
nerves were too bad?



















Duration of present episode of pain
Number of previous attacks
Total duration of history
Working diagnosis
(after assessment of initial investigations)
Emergency Surgery (please ring one)
Yes Review Unlikely No
Psychosocial Problems
Is there a problem? (please ring one) Yes No
If yes, is the nature of the problem obvious?
APPENDIX 10
Consultant: Mr Tom Bates
Research assistant: Mrs M Harrison












You will remember that you were admitted to the William Harvey Hospital in <date>
with abdominal pain. You may recall that when you were admitted, you filled some
questionnaires.
Because we are interested in the after-effects of hospital admission for this type of
abdominal problem, we would be very grateful if you would kindly answer the following
questions, together with the enclosed questionnaires (on both sides) and return them in
the envelopes provided. There quite a few questions but they are meant to be answered
fairly quickly. If you have any queries, then please phone.
Your answers will be treated in the strictest confidence. Thank you for your co¬
operation.
Yours sincerely,
Simon Fraser, Honorary Registrar.
Tom Bates, Consultant
Questions
1) Do you still suffer from the pain which caused your first admission to hospital?
YES/NO
2) Was your pain adequately dealt with at the time of hospital admission? YES/NO
3) Did you require further medical attention, hospital attendance or admission? YES/NO
If so, please state which doctor or which hospital and when:
4) Would you like another appointment to be seen at the William Harvey Hospital?
YES/NO
APPENDIX 11 Spielberger anxiety trait questionnaire
3 Date
ACTIONS: A number of statements which people have used to 1 = Almost never
-ibe themselves are given below. Read each statement and then 2 = Sometimes
:en the appropriate number to the right of the statement to 3 = Often
ate how you generally feel. There are no right or wrong 4 = Almost always
ers. Do not spend too much time on any one statement but give
inswer which seems to describe how you generally feel.
eel pleasant 12 3 4
eel nervous and restless 12 3 4
eel satisfied with myself 12 3 4
/ish I could be as happy as others seem to be 12 3 4
eel like a failure 1 2 3 4
eel rested 12 3 4
m "calm, cool, collected" 12 3 4
eel that difficulties are piling up so that I cannot overcome them
12 3 4
mrry too much over something that really doesn't matter 12 3 4
m happy 12 3 4
ave disturbing thoughts 12 3 4
ick self-confidence 12 3 4
3el secure 12 3 4
lake decisions easily 12 3 4
sel inadequate 12 3 4
m content 12 3 4
ne unimportant thought runs through my mind and bothers me 12 3 4
ake disappointments so keenly that I can't put them out of my
id 12 3 4
m a steady person 1 2 3 4
et in a state of tension or turmoil as I think over my recent
icerns and interests 12 3 4
lestions 1,3,6,7,10,13,14,16,19 subtract from 5; add to rest)
PPENDIX 12
1. Has the operation been as successful as you had hoped? YES NO
If not, please say in what way.
2. Do you wish you had been offered the operation much sooner?
YES NO
For the following questions, please circle the response which most closely agrees
with your present state.
3. Following your operation, how do you grade your health?
Worst possible Worse Same Better Best possible
4. How has the operation affected your quality of life?
Much worse Worse Same Better Much better
5. How is your efficiency at work affected?
Much worse Worse Same Better Much better
6. How is your social life affected?
Much worse Worse Same Better Much better
7. How is your sex life affected?
Much worse Worse Same Better Much better
8. How are your interests and hobbies affected?
Much worse Worse Same Better Much better
9. How have your holidays been affected?
Much worse Worse Same Better Much better
10. How much time did you have to take off work or normal activity after the
operation?
